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Purified Herba leonuri (pHL) is a compound isolated from the Chinese Motherwort 
plant. It has been shown to have a broad spectrum of pharmacological properties but 
has not been tested for any beneficial effects in traumatic brain injury (TBI). The first 
part of this study aims to investigate the effects of pHL on different parameters of 
damaged brain tissue following TBI in the rat. The rats were given orally, pHL 
(400mg/kg) or vehicle, daily for one week starting from the day after TBI induction. 
Sham-operated and vehicle-treated animals were used as control groups. At the end of 
the treatment period, the animals were sacrificed and brain samples were collected for 
analysis. The lesion area was measured and the number of apoptotic cells in the cortex 
were estimated. The number of apoptotic-like cells, neurons, astrocytes and microglia 
in the hippocampus were also counted. The activities of superoxide dismutase (SOD), 
catalase (CAT), glutathione peroxidase (GPx) and glutathione-S-transferase (GST) in 
the brain were measured. In addition, the expressions of Bax, Bcl-xL, PARP and 
caspase-3 in the brain tissue were quantified. The results showed that there was 
reduced lesion area and number of apoptotic cells in the injured cortex. A significant 
reduction in the number of apoptotic hippocampal cells, neuronal loss, astrocytes and 
microglia was observed in the pHL-treated group compared with the vehicle group. 
pHL significantly increased the activities of SOD, CAT and GPx in brain tissue but 
did not affect the activity of GST. Furthermore, the expressions of Bax and PARP 
were significantly reduced while the expressions of Bcl-xL and caspase-3 were 




The second part of this study aims to investigate the effects of Leonurine (Leo) on 
TBI. Leo was synthesized from syringic acid by carbonylation, reaction with thionyl 
chloride (SOCl2), and the Gabriel reaction. The rats were given orally, Leo (60mg/kg) 
or vehicle, daily for one week starting from the day after TBI induction. Sham-
operated and vehicle-treated animals were used as control groups. At the end of the 
treatment period, the animals were sacrificed and brain samples were collected for 
analysis. In this study, only antioxidant activities and anti-apoptotic effects were 
chosen for observation. Leo increased the activities of SOD, CAT, GPx and GST in 
brain tissue but only the increase in SOD was significant. Furthermore, the 
expressions of Bax and PARP were significantly reduced while the expressions of 
Bcl-xL and caspase-3 were significantly increased with Leo treatment compared to 
vehicle.  
 
The third part of this study aims to compare the effects of pHL and Leo on TBI. Using 
DPPH free radical scavenging assay, the antioxidant capacity of both compounds 
were determined. The antioxidant activities and anti-apoptotic effects were also 
compared. pHL has a higher antioxidant capacity as compared to Leo. Similarly, pHL 
has better antioxidant and anti-apoptotic effects than Leo, as it shows a higher 
percentage increase/decrease of the treatment outcome compared to the TBI group.  
The difference in activities of SOD, CAT and GPx was significant between both 
treatment groups. Furthermore, there is also significant difference in the expressions 




In summary, our data show that both pHL and Leo confer protection to brain tissue 
following TBI. This protection may be mediated through antioxidative and 
antiapoptotic mechanisms. However, the protective effects of pHL are better and this 
may be due to its higher antioxidant capacity, which is able to reduce oxidative stress 
and hence apoptosis more effectively. Further studies are required to give an in-depth 






Objectives and Structure of Thesis 
 
1)    Objectives 
The main objectives of this work are three-fold: 
 
1.1  Studies to verify the possible therapeutic potential of pHL in rats subjected 
to TBI:  
In experiment I, a pilot study was conducted to observe the effect of pHL on rats 
subjected to TBI via a few parameters: lesion area and number of terminal TUNEL-
positive apoptotic cells on the cortex, the number of apoptotic-like cells, neurons, 
astrocytes and microglia in the hippocampus. Antioxidant measurements and anti-
apoptotic assessment were carried out to identify the possible protective mechanisms 
of pHL. 
 
The following parameters were measured: 
• The lesion area and the number of apoptotic cells in the cortex  
• The number of apoptotic-like cells, neurons, astrocytes and microglia in the 
hippocampus.  
• SOD, CAT, GPx and GST activities in the brain tissue to identify the effects 
of pHL on antioxidant mechanisms. 
• Expressions of BAX, Bcl-xL, procaspase-3 and cleaved PARP  in the brain 






1.2  Studies to address the effects of Leo on antioxidant activity and the 
expression of apoptotic pathway proteins in rats with TBI:  
In experiment II, a key compound of pHL (Leo) was targeted to identify if it is one of 
the active ingredients of pHL for neuroprotection.  
 
The following parameters were measured: 
• SOD, CAT, GPx and GST activities in brain tissue to identify the effects of 
Leo on antioxidant mechanisms. 
• Expressions of BAX, Bcl-xL, procaspase-3 and cleaved PARP  in brain tissue 
to identify the effects of Leo on anti-apoptotic mechanisms. 
 
1.3  Studies to compare pHL and Leo on anti-oxidant and anti-apoptotic effects 
in rats with TBI:  
In experiment III, the antioxidant capacity of both compounds were evaluated by the 
DPPH free radical scavenging assay. This will determine which compound has a 
higher antioxidant capacity. In particular, the antioxidant and anti-apoptotic effects 
demonstrated in experiment I and experiment II will be compared. 
 
2)    Structure of thesis 
This study is reported as follows: 
 
Chapter 1: General Introduction 
This chapter starts with an introduction of TBI and changes associated with it in 
section 1. A brief TBI epidemiology is presented, followed by types of TBI and its 
classifications and symptoms. Next, a review of the scientific literature relevant to 
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TBI pathophysiology, involvement of excitotoxicity, oxidative stress, inflammation 
and apoptosis is introduced. Lastly, the different types of animal model used in TBI 
will be described in detail. 
 
In section 2, pharmacological management of TBI will be reviewed along with the 
description of primary successes of clinical trial on TBI therapy, and their limitation 
of usage on patients. Current therapies include drugs to control intracranial pressure 
and edema, NMDA receptor antagonists, calcium channel blocking and anti-
inflammatory agents, free radical scavengers, inhibitors of apoptosis, neurotrophic 
factors, multipotential drugs and herbal medicines. 
 
In section 3, the importance of study on the potential neuroprotective effects of 
natural products, particularly TCM are highlighted. We also reviewed the rationale of 
focusing on Chinese Herbs as potential therapeutic agent with a few examples. The 
later part of this section introduces Herba leonuri, pHL and Leo in more details. 
 
Chapter 2: Materials and Methods 
This chapter explains the three experimental protocols: 
 
Experimental protocol I: Cerebral Protection of pHL on rats with TBI. 
Experimental protocol II: Leo protects rats with TBI through antioxidant and anti-
apoptotic mechanisms.  
Experimental protocol III: Comparison of the effects of pHL and Leo in TBI based on 
antioxidant and anti-apoptotic mechanisms. 
Experimental techniques used to obtain the results are also illustrated in this chapter. 
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Chapter 3: Results 
Results obtained from the three experimental protocols are presented in this chapter. 
 
Chapter 4: Discussion 
Discussion based on three parts of the experiment is brought out in this chapter. 
 
Chapter 5: Conclusion and Future Studies 
This chapter concludes the whole thesis with an explanation of the outcomes of this 
project in relation to the initial objectives. Limitations of the study will also be 
discussed. The possible areas of research which could be further investigated and 


































1.1:   Traumatic Brain Injury (TBI) and Changes Following TBI 
 
1.1.1    TBI 
TBI is one of the leading causes of mortality and long-term disability in the western 
world. It is an extremely common condition, accounting for 50,000 deaths and 
235,000 hospitalizations yearly (Langlois JA, 2004). The prevalence of individuals 
with chronic TBI-related problems in the US is 5.3 million (Thurman et al., 1999), 
and many are coping with physical, cognitive and behavioral problems. According to 
the Centers for Disease Control and Prevention (CDC) in the United States of 
America (USA), the top leading causes of TBI are falls followed by motor vehicle 
accidents, sports or recreation related accidents and assaults. 
 
Human TBI can be caused by an enormous heterogeneity of forces which impact the 
head (Kunz et al., 2010). Two major forms of TBI have been classified in humans: 
closed and penetrating; the nature of forces which act on the head as well as the 
amount of mechanical energy transmitted determine the type of TBI (Morales et al., 
2005b). Closed TBI is further sub-classified into static and dynamic loading, 
depending on the velocity of the force transmission process (Morales et al., 2005b). 
The more common mechanism causing TBI is dynamic loading. The purpose of 
categorizing TBI helps to isolate a distinct pattern of pathophysiological events which 




TBI can be classified into mild, moderate and severe categories (Saatman et al., 
2008). The Glasgow Coma Scale (GCS) is the most commonly used system to 
classify TBI severity. It grades a person’s level of consciousness on a scale of 3-15 
based on verbal, motor and eye-opening reactions to stimuli. It is generally agreed 
that a TBI with a GCS of 13 or above is mild, 9-12 is moderate and 8 or below is 
severe (Parikh et al., 2007). This grading system has its limitations in predicting 
outcomes so other parameters have been used to judge the severity of TBI. These 
parameters include duration of post-traumatic amnesia (PTA), duration of loss of 
consciousness (LOC) and checking for swelling and/or focal lesions by neuroimaging. 
The seriousness of TBI is often underestimated because physical impairments are 
frequently mild or absent while the more disabling problems of cognitive and 
behavioral impairments are often overlooked or misdiagnosed by medical 
professionals. Therefore, the after effects of TBI may be a long term burden to people 
where impairments or disabilities are present. 
 
The symptoms of TBI depend on whether it is a diffuse or focal injury and also the 
part of the brain which is affected. It also depends on the severity of the injury. With 
mild TBI, the patient remains conscious or lose consciousness for a few seconds or 
minutes. Other symptoms of mild TBI include headache, vomiting, nausea, lack of 
motor coordination, dizziness and difficulty balancing (Kushner, 1998). Cognitive and 
emotional symptoms include behavioral or mood changes, confusion and having 
trouble with memory and concentration. These symptoms may be present in both mild 
and moderate TBI. In moderate or severe TBI, a person may show more serious 
symptoms like persistent headaches, repeated vomiting or nausea, convulsions, 
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slurred speech, weakness or numbness in the limbs, loss of coordination or agitation. 
In addition, there are long-term symptoms like changes in social behavior, deficits in 
social judgment and cognitive changes especially problems with sustained attention, 
processing speed and executive functioning (Busch et al., 2005; Kim, 2002; 
McDonald et al., 2003; Ponsford et al., 2008). 
 
1.1.2    Pathophysiology of TBI 
1.1.2.1    Primary and Secondary Injury 
After TBI, the damage of brain tissue can be caused by primary and secondary injury 
mechanisms. The primary injury refers to the direct effects of mechanical injury on 
the brain tissue. A primary injury can incur focal and/or diffuse damage to the brain. 
Examples of focal injuries are epidural, subdural or intracerebral hematomas and 
brain contusions, while diffuse damage refers to diffuse axonal injuries (DAI) (Kunz 
et al., 2010). Primary injury usually causes skull fracture and abruptly disrupts the 
brain parenchyma, with shearing and tearing of blood vessels and brain tissue 
(Gentleman et al., 1995a; Povlishock and Christman, 1995b). This will then trigger a 
cascade of events characterized by activation of molecular and cellular responses,  
which lead to secondary injury (Leker and Shohami, 2002). Secondary injury takes 
hours or days to surface and is known to be a complex process. The initial events 
include damage to the blood–brain barrier, release of inflammatory factors, overload 
of free radicals, excessive release of the neurotransmitter glutamate (excitotoxicity), 
influx of calcium and sodium ions into neurons and mitochondria dysfunction (Park E 
Fau - Bell et al.). As a result, neurons can potentially be killed when the injured axons 
in the brain’s white matter separate from their cell bodies. Other factors which 
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subsequently contribute to secondary injury are reduced blood flow to the brain, 
ischemia, cerebral hypoxia, cerebral edema and raised intracranial pressure (Jain, 
2008). Together, the primary and secondary events eventually lead to brain damage. 
 
 
Figure 1-1: A diagram to illustrate the sequence of events following TBI        
[Adapted from (Jain, 2008)] 
 
 
1.1.2.2    Excitotoxicity 
After TBI, excitatory amino acid neurotransmitters such as glutamate and aspartate 
are released in an uncontrolled manner to the injured areas. Within minutes after 
neurons are exposed to glutamate, ionophoric NMDA and AMPA receptors are 
activated, the membrane is depolarized and this leads to the influx of calcium, sodium 
and water into cells of the lesioned region (Obrenovitch and Urenjak, 1997; Palmer et 
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al., 1993). This will cause cytotoxic edema and massive disruption of ionic 
homeostasis due to the lack of energy stores in the traumatized region. Intracellular 
calcium level which is also elevated, causes an increase in cellular oxidative stress 
which leads to cell damage. It activates various enzymes such as lipases, proteases 




Figure 1-2: A diagram to summarise post traumatic excitotoxicity leading to cell death 
[Adapted from (Ringel and Schmid-Elsaesser, 2001)] 
 
 
1.1.2.3    Oxidative Stress 
Oxidative stress is the state of imbalance between two opposing antagonistic forces, 
reactive oxygen species (ROS) and antioxidant, in which the effects of former 
predominate over the compensating action of latter (Fernandez-Checa et al., 1997).  
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Nitric oxide (NO˙) and superoxide (O2˙¯) are two major free radicals responsible for 
oxidative stress. These two free radicals could react with each other to produce 
powerful oxidant peroxynitrite (ONOO¯). Other ROS includes hydrogen peroxide 
(H2O2) and hydroxyl radical (OH˙). As reported by Zhu et al., there are many possible 
mechanisms of free radical production. Besides the basal level generation of O2˙¯ by 
the mitochondria, disruption of the mitochondria electron transport chain can result in 
autoxidation of flavoprotein and ubisemiquinone to form O2˙¯ (Zhu et al., 2004). 
Endothelial cells also produce free radicals such as NO˙ which is a major component 
of endothelial-derived relaxing factor (Zhu et al., 2004). 
 
The brain is very vulnerable to oxidative damage due to its high membrane surface to 
cytoplasm ratio; non-replicating neurons; relatively low antioxidant capacity and 
repair mechanism activity; high rate of oxidative metabolite activity and intensive 
production of reactive oxygen metabolites (Evans, 1993; Reiter, 1995). Prolonged 
elevations of intracellular calcium results in the formation of superoxide anion 
radicals by the respiratory chain, as well as by cytosolic enzymes, such as xanthine 
oxidase (Juurlink and Paterson, 1998). In the extracellular compartment, autoxidation 
of catecholamines is an alternate pathway for free radical production. This leads to an 
increase in oxidative stress.  
 
The increased production of ROS is due to excitotoxicity and exhaustion of the 
endogenous antioxidant system (e.g. SOD, GPx, CAT). This leads to peroxidation of 
cellular and vascular structures, protein oxidation, cleavage of deoxyribonucleic acid 
(DNA) and inhibition of the mitochondrial electron transport chain (ETC) (Chong et 
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al., 2005; Shao et al., 2006). The brain contains high levels of redox-active metals 
such as iron, copper and manganese. During trauma, the mobilization of these metals 
may occur and get exposed to reducing agents. As a result, highly toxic radicals are 
produced and cause oxidative damage (Shohami et al., 1997). Free radicals also block 
mitochondrial respiration and facilitate the formation of mitochondrial permeability 
transition pore (MPTP), leading to mitochondrial swelling and cell death. As a result 
of oxidative stress, inflammatory processes and early or late apoptotic programmes 
are induced (Chong et al., 2005).  
 
 
Figure 1-3: A schematic representation of major intracellular pathways in the 
generation of free radicals after CNS injury. XDH, xanthine dehydrogenase; XO, 
xanthine oxidase; NOS, nitric oxide synthase (neuronal, inducible and endothelial); 
COX-2, cyclooxygenase-2; CuZnSOD, copper-zinc superoxide dismutase; GSPx, 




1.1.2.4    Inflammation 
TBI induces a complex array of inflammatory tissue responses. After a traumatic 
insult, cellular mediators including proinflammatory cytokines, prostaglandins and 
free radicals are released. As early as 1 hour after traumatic insults, proinflammatory 
cytokines such as tumour necrosis factor-alpha (TNFα), interleukin-1 (IL-1) and 
interleukin-6 (IL-6) are activated and secreted (Shohami et al., 1994a; Taupin et al., 
1993). These processes induce chemokines and adhesion molecules and subsequently 
recruit immune and glial cells in a parallel and synergistic manner (Lucas et al., 2006; 
Potts et al., 2006). For example, activated polymorphonuclear leukocytes can adhere 
to endothelial cell layers and infiltrate injured tissue along with macrophages and T-
cell lymphocytes (Zhang et al., 2006). Cellular adhesion molecules such as 
intracellular adhesion molecule (ICAM), endothelial leukocyte adhesion molecule 
(ELAM), vascular adhesion molecules (VCAM-1) and tissue metalloproteinases are 
also upregulated and facilitate the penetration of leukocytes through the blood brain 
barrier (BBB) (Pantoni et al., 1998). In response to these inflammatory processes, 
injured and adjacent tissue will be eliminated, and within hours, days or weeks, 
astrocytes will produce microfilaments and neurotropines to synthesize scar tissue 
(Fabricius et al., 2006). The direct release of neurotoxic mediators or indirect release 
of nitric oxide and cytokines in the affected region affects the extent of  tissue 
damage. In addition, the release of vasoconstrictors (prostaglandins and leukotrienes), 
the destruction of microvasculature through adhesion of leucocytes and platelets, the 
BBB lesion and edema formation further reduce tissue perfusion and aggravate 




Inflammatory response after injury is found to have detrimental effects in the early 
phase (within hours), but there have been studies to show that this response is 
beneficial in the late (days-weeks) phase. In vitro studies have demonstrated 
detrimental effects of TNFα, causing neuronal, endothelial, glial cell damage and 
induction of apoptosis (Hisahara et al., 1997; Westmoreland et al., 1996). 
In a study of TNFα-deficient (TNF -/-) mice, attenuation of cognitive and 
neurological motor deficits was observed in the first week following TBI. However, 
up to 4 weeks post-injury, TNF -/- mice were significantly worse in cognitive and 
neurological motor function when compared to wild-type controls. This suggests that 
early, but not late inhibition of TNFα might improve the outcome and recovery 
following TBI (Scherbel et al., 1999). It was also reported that IL-6 is 
neuroprotective, promoting survival and differentiation of neurons and inducing 
neurotrophin expression in response to central nervous system (CNS) injury 
(Kossmann et al., 1996; Munoz-Fernandez and Fresno, 1998). The role of IL-6 and 
TNFα remains elusive as both cytokines may be attributed with neuroprotective and 
neurotoxic properties. Another cytokine interleukin-10 (IL-10) which is involved in 
immunoregulation and anti-inflammation helps to protect cells against damage 
(Bethea et al., 1999; Knoblach and Faden, 1998). 
 
1.1.2.5    Apoptosis 
Cells dying after brain trauma can either die of necrosis or apoptosis. Necrosis occurs  
in response to severe mechanical or ischemic/hypoxic tissue damage, along with 
excessive release of excitatory amino acid neurotransmitters and metabolic failure, 
which disrupt cell viability. Necrosis is irreversible massive cell death characterized 
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by shrunken cells with darkened nuclei, swelling of cytoplasm and organelles and loss 
of membrane integrity which results in cell lysis and release of cellular content that 
causes local inflammation to surrounding tissue (Taoufik and Probert, 2008). In 
contrast, apoptosis is an orderly process of energy dependent programmed cell death 
characterized by morphological features such as cell shrinkage, membrane blebbing, 
chromatin condensation and DNA fragmentation (Nakka et al., 2008). Cells 
undergoing apoptosis are morphologically intact immediately after the primary insult 
but only show changes hours or days later. Apoptotic cells will be recognized and 
removed by phagocytosis to avoid inflammation and minimize the damage and 
disruption of neighbouring cells (Taylor et al., 2008). A more unique morphological 
characteristic of neuron undergoing apoptotsis is the neurite fragment (dendrites and 
axons) that occurs during the early cell death process (Taoufik and Probert, 2008). 
Mixed morphologies of apoptosis and necrosis observed could be explained by the 
initiation of apoptosis which is later overtaken by the molecular event associated with 
necrosis (Roy and Sapolsky, 1999).  
 
The balance between numerous pro- and anti-apoptotic factors may contribute to the 
induction of apoptosis, this includes the formation of free radicals, increase in 
excitatory amino acids and intracellular Ca2+, Bcl proteins, p53 and other transcription 
factors (Raghupathi et al., 2000). Apoptosis in the brain is regulated by both caspase-
dependent and caspase-independent mechanisms. Caspases are aspartate-specific 
cysteine proteases constitutively expressed in the brain and are activated by intrinsic 
and extrinsic signals (Galluzzi et al., 2009; Raghupathi et al., 2000; Yuan and 
Yankner, 2000). The two pathways, extrinsic pathway and intrinsic pathway are 
shown in (Figure 1-4). Extrinsic pathway initiates apoptosis through the engagement 
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of plasma membrane death receptors, also referred as “death receptor pathway” (Ashe 
and Berry, 2003; Eldadah and Faden, 2000). Death receptors belong to the tumor 
necrosis factor receptor (TNFR) family. They transmit the apoptotic signal through 
binding of death ligand. Fas is one of the best characterized family members and its 
preferred ligand is (Fas ligand) FasL (Ashe and Berry, 2003). Subsequently, a 
cytoplasmic death-inducing signaling complex (DISC) is assembled, initiator caspases 
are activated and apoptosis is executed by cleavage of downstream targets (Danial and 
Korsmeyer, 2004; Eldadah and Faden, 2000). Generally, there are two types of Fas-
mediated apoptosis. Type 1 requires the activation of caspase 8 that is closely 
followed by the activation of caspase 3. Type II has limited activation of caspase 8 
and is responsible for the release of cytochrome c and second mitochondria-derived 
activator of caspases (SMAC) from the mitochondria (Ashe and Berry, 2003). There 
are also reports on Fas/FasL system that it is involved in neuronal apoptosis following 
TBI (Beer et al., 2000a). (Ashe and Berry, 2003).  
 
The occurrence of a traumatic insult is followed by elevated intracellular levels of 
calcium, reactive oxygen species (ROS), glutamate and finally DNA damage. These 
events are intrinsic activators of apoptosis and results in the activation of BID to its 
truncated active form tBID as shown in (Figure 1-4). By damaging mitochondrial 
membranes, both pathways directly or indirectly lead to the activation of caspases 
(Eldadah and Faden, 2000). Once activated, caspases cleave a number of downstream 
substrates that include other executioner caspases, DNA repair enzymes such as 
PARP, cytoskeletal proteins, presenilin, huntingtin, and inhibitor of caspase-activated 
DNase (ICAD) (Budd et al., 2000; Nicotera and Lipton, 1999; Salvesen, 2001). After 
the disruption of mitochondria or the opening of MPTP, mitochondrial proapoptotic 
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proteins such as cytochrome c, SMAC, serine protease HtrA2/Omi will be released 
into the cytoplasm. Once released, these proteins will be involved in caspase-
dependent apoptotic pathway.  
 
 Cytochrome c, a water soluble mitochondrial protein, is an essential component of 
the mitochondrial respiratory chain. Once released from the mitochondria, 
cytochrome c induces formation of the “apoptosome” complex by binding to cytosolic 
protein Apaf-1 and procaspase 9. The apoptosome activates caspase 9, leading to 
sequential activation of downstream caspases and eventually activates caspase 3 as an 
executor of apoptosis (Galluzzi et al., 2009). The release of cytochrome c from 
mitochondria depends on the integrity of the mitochondrial outer membrane, which is 
regulated by the Bcl-2 family of proteins. This family is divided into pro- (e.g. Bid, 
Bax, Bak, Bad) and anti-apoptotic (e.g. Bcl-2, Bcl-xL) proteins (Danial, 2007); they 
regulate membrane permeabilization in an ordered series of events (Lovell et al., 
2008) or inhibit membrane permeabilization by competition between anti- and pro-
apoptotic family members (Billen et al., 2008).  
 
In the traumatically injured brain, the temporal and spatial distribution of apoptosis is 
highly dependent on the type and severity of injury. In both experimental brain injury 
and human head injury, apoptotic cells have been observed adjacent to necrotic cells, 
both in the vicinity and remote from the contusion sites (Conti et al., 1998; 
Raghupathi et al., 2000; Raghupathi, 2004). Neurons, oligodendrocytes and astrocytes 
have all been shown to die from apoptosis following TBI (Newcomb et al., 1999).  
Apoptotic cell death has been reported in mice, rats and humans following TBI (Clark 
et al., 1999; Fox et al., 1998; Rink et al., 1995). Caspase activation primarily localized 
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in neurons has been recorded in the injured cortex and hippocampus 1 hour following 
left fluid percussion injury (LFPI) (Knoblach et al., 2002). Similarly, after rodent and 
human TBI, caspase activation was reported from 6 to 72 hours in the injured cortex 
and hippocampus. This was observed in neurons, astrocytes, and to a lesser extent 
oligodendrocytes (Beer et al., 2000b; Ringger et al., 2004). 
 
 
Figure 1-4: A schematic diagram of apoptosis. There are considerable cross talks 
between intrinsic and extrinsic pathway of apoptosis which could ultimately lead to 
cell death. (Adapted from (Nakka et al., 2008)) 
 
 
1.1.3    Animal Models of TBI 
As the initial impact from TBI on the brain tissue causes immediate cell death which 
is irreversible, treatments focus on the inhibition of secondary injury cascades. 
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Nonetheless, no effective neuroprotective treatment is currently available 
(Doppenberg et al., 2004; Xiong et al., 2009). The use of animal model is necessary 
for the understanding of secondary injury processes to develop novel therapies. The 
entire spectrum of events which occur in TBI cannot be covered by one single rodent 
model. Therefore, several mouse and rat experimental models have been established 
to replicate the different pathogenic characteristics of TBI. Of these, the most 
commonly used models are weight-drop injury, fluid percussion injury (FPI) and 
cortical contusion injury (CCI). However, the entire spectrum of events that might 
occur in TBI cannot be covered by one single rodent model. 
 
1.1.3.1    Weight-drop models 
The weight-drop models use the gravitational forces of a free falling weight to 
produce a largely focal (Shapira et al., 1988; Shohami et al., 1988) or diffuse brain 
injury (Foda and Marmarou, 1994; Marmarou et al., 1994) The impact of the free 
falling weight is delivered to the exposed skull in rat (Shapira et al., 1988) and mouse 
(Chen et al., 1996) or the intact dura in rat (Feeney et al., 1981). The weight-drop 
models can induce either focal or diffuse brain injury. Animals are placed on non-
flexible platforms to minimize dissipation of energy and create focal brain injury 
(Flierl et al., 2009; Shapira et al., 1988; Shohami et al., 1988). In contrast, flexible 
platforms like those with elastic springs (Blaha et al., 2010) or those made of foam 
(Adelson et al., 1996; Foda and Marmarou, 1994; Marmarou et al., 1994) allow the 
head to accelerate and create diffuse brain injury. The severity of head trauma can be 
varied by using different weights and/or heights of the weight-drop. The weaknesses 
of this model are high mortality rate due to apnea and skull fractures and it is not 
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highly reproducible. However, there are some measures to prevent these weaknesses. 
When the impact is delivered to the exposed skull, the risk of skull fractures can be 
reduced by the silicone-cover on the impacting rod (Flierl et al., 2009). On the other 
hand, apnea can be reduced by early respiratory support and the usage of animals with 
a certain age and weight (Foda and Marmarou, 1994; Marmarou et al., 1994). 
 
There are three commonly known weight-drop model: Feeney’s weight-drop model, 
Shohami’s weight-drop model and Marmarou’s weight-drop model. A brief 
description on the characteristics of each model will be discussed below. 
 
Feeney’s weight-drop model 
An impact is delivered to the intact dura (Dail et al., 1981; Feeney et al., 1981) which 
results in a cortical contusion with hemorrhage (Morales et al., 2005b) and damage of 
the blood brain barrier (BBB) (Bellander et al., 1996; Mikawa et al., 1996). 
Inflammatory processes lead to activation of microglia and astrocytes, activation of 
the complement system and invasion of neutrophils and macrophages (Bellander et 
al., 1996; Feeney et al., 1981; Isaksson et al., 2001). The pattern of post-traumatic cell 
death depends on the severity of impact (Lindh et al., 2008). 
 
Shohami’s weight-drop model 
This model is later introduced for creating closed-head injury using a weight-drop 
impact to one side of the unprotected skull. The injury severity in this model is 
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dependent on the mass and falling height of the weight used. Generally, mild weight-
drop injuries are associated with a diffuse injury pattern whereas more severe weight-
drop injuries produce a focal contusion. Heavier weights and/or increased falling 
height produces an ipsilateral cortical brain contusion and BBB disruption followed 
by brain edema, activation of the complement system, cell death evolving from 
contusion site and invasion of inflammatory cells (Flierl et al., 2009; Leinhase et al., 
2006; Leinhase et al., 2007; Shohami et al., 1988; Shohami et al., 1994b). Lighter 
weights and/or shorter fall height results in a concussive-like brain injury, bilateral 
cell loss, short-term edema and long-term cognitive deficits (Morales et al., 2005b). 
 
Marmarou’s weight-drop model (Impact acceleration model) 
In this model, the “whole head” motion allows the head to accelerate at impact, 
resulting in diffuse brain injury (Foda and Marmarou, 1994; Marmarou et al., 1994). 
Depending on the severity of injury, the induced brain injury results in hemorrhages, 
neuronal cell death, astrogliosis, diffuse axonal injury and cytotoxic brain edema 
(Cernak, 2005a; Ding et al., 2009; Marmarou et al., 1994; Morales et al., 2005b). 
 
Taken together, weight-drop models provide a straightforward way to assess brain 
injuries close to the clinical conditions ranging from focal to diffuse brain injuries. 
 
1.1.3.2    Fluid percussion injury (FPI) models 
FPI models produce brain injury by rapidly injecting fluid volumes onto the intact 
dural surface through a craniotomy. The craniotomy is made either centrally, over the 
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sagittal suture midway between bregma and lambda, or laterally, over the parietal 
cortex. The force of the fluid pressure pulse can be adjusted to achieve different levels 
of injury severity. The central (CFP) and lateral (LFP) fluid percussion injury models 
produce a mixed type of brain injury. The pathology of brain injury includes cortical 
contusion, hemorrhage and a cytotoxic and/or vasogenic brain edema which is 
bilateral for CFP injury or ipsilateral for LFP injury (Cernak, 2005a; Morales et al., 
2005b; Yamaki et al., 1994). Downstream progression of brain damage is 
accompanied by astrogliosis, diffuse axonal injury, inflammatory events, 
neurodegeneration and cognitive dysfunction (Kelley et al., 2007; Myer et al., 2006; 
Thompson et al., 2005; Yamaki et al., 1998). The FPI model is useful in the study of 
posttraumatic dementia, in particular the LFP model is suitable for studying 
posttraumatic epilepsy. Although the FPI model has been widely used in rats, there 
are still variability in injury parameters reported by different research groups. One 
crucial factor in determining the outcome severity in this model seems to be the 
position of the craniotomy as a small shift in the craniotomy site is associated with 
distinct differences in neurological outcome, lesion location and size (Floyd et al., 
2002; Vink et al., 2001). Once the method is fine-tuned to obtain a standardized 
outcome in severity and pathophysiology, the induced brain trauma should be highly 
reproducible. 
 
1.1.3.3    Controlled cortical impact (CCI) injury model 
CCI models utilize a pneumatic pistol to deform the exposed dura laterally, allowing 
controlled impact and quantifiable biomechanical parameters. As a result, graded and 
reproducible brain injury can be produced. Depending on the severity of injury, CCI 
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results in an ipsilateral injury with cortical contusion, hemorrhage and BBB disruption 
(Dhillon et al., 1994). Following these events, neuronal degeneration and cell death, 
astrogliosis, microglial activation, inflammatory events and cognitive deficits are also 
observed (Hall et al., 2008; Igarashi et al., 2007; Sandhir et al., 2008; Smith et al., 
1995). The pathophysiology of secondary injury can be studied easily as CCI 
produces a predominantly focal brain injury. CCI is an important model to study 
posttraumatic brain edema formation as it causes a cytotoxic and vasogenic brain 
edema (Elliott et al., 2008) . In addition, the posttraumatic seizure activity is similar to 
injury-induced epilepsy in humans, therefore it can be used to study the 














Table 1-1: Description of common experimental rodent models of closed head injury. 
(Adapted from (Albert-Weissenberger and Siren, 2010)) 
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1.2:    Pharmacological Management of TBI 
As mentioned before, the direct mechanical damage of TBI cannot be mended, 
therefore therapeutic targets focus on secondary biochemical changes that contribute 
to subsequent tissue damage and associated neuronal cell death. Although treatments 
that limit secondary tissue loss and/or improve behavioral outcomes have been well 
established in multiple animal models of TBI, translation of such neuroprotective 
strategies to human injury have been disappointing, with the failure of many 
controlled clinical trials. The goals of pharmacological therapy of TBI are to reduce 
mortality as well as improve motor, sensory and cognitive outcomes in TBI patients, 
to enhance their quality of life. 
 
1.2.1    Control of intracranial pressure and cerebral edema 
Currently, the most crucial management of acute severe TBI is the control of cerebral 
edema and raised intracranial pressure. Treatments for these conditions are very 
limited and include osmotherapy by the administration of hypertonic mannitol or 
hypertonic saline and in severe cases, by surgical decompression (Jain, 2008). 
Osmotherapy has limited benefits as the healthy brain will shrink along with the 
damaged area when water is removed (Jain, 2008). There is also evidence that 
excessive administration of mannitol increases pressure within the skull and worsens 
brain swelling (Wakai et al., 2007). Hyperbaric oxygen therapy is another option but 






1.2.2    N-methyl-D-aspartate (NMDA) receptor antagonists  
Glutamate release is known to be one of the initial events in the pathophysiological 
cascade following TBI. Glutamate acts postsynaptically on three families of 
ionotropic receptors, NMDA, AMPA, and kainite receptors (Meldrum, 2000; Tapiero 
et al., 2002). Another class of receptor is the metabotropic glutamate receptor 
(mGluR), which acts via a messenger (G protein) to modulate biochemical pathways 
and ion channels. Three subgroups of mGluRs have been characterized, group I 
(mGluRs1, mGluRs5), group II (mGluRs2, mGluRs3), and group III (mGluRs 4–8). 
In contrast to ionotropic receptors, mGluRs modulate the release of neurotransmitters 
(Platt, 2007). Examples of NMDA antagonists evaluated in experimental TBI include 
dextromethorphan and dextrorphan, ketamine, MK-801, magnesium, HU-211 
(dexanabinol) and remacemide hydrochloride, all of which have been shown to 
decrease neuronal death, edema and/or neurological dysfunction after experimental 
TBI (Lea and Faden, 2001; McIntosh et al., 1998). Although many studies have 
reported NMDA antagonists showing potential neuroprotective properties following 
experimental TBI, all clinical trials using this class of compounds have failed. The 
reasons for the lack of successful clinical translation can be due to the complicated 
process occurring in TBI, but may also be due to the short therapeutic window of 
NMDA antagonism (Marklund et al., 2006). 
 
1.2.3    Calcium channel blocking agents 
Calcium antagonists have been used in an attempt to prevent cerebral vasospasm after 
injury, maintain blood flow to the brain, and thereby prevent further damage (Maeda 
et al., 2005). Nimodipine is a selective L-type calcium channel blocker and its 
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treatment was first reported to be used in patients with severe TBI in 1984 (Kostron et 
al., 1984). However, further randomized controlled trials (RCTs) performed showed 
considerable uncertainty over their effects. When patients with traumatic 
subarachnoid hemorrhage were administered nimodipine, there were increased side 
effects and no significant improvements compared to the placebo group (Langham et 
al., 2003; Vergouwen et al., 2006). SNX-111, also known as ziconotide, is an N-type 
calcium channel blocker (Verweij et al., 2000). It has a long therapeutic window and 
is effective in improving mitochondrial function after TBI in rats, but it is found to 
cause higher mortality in patients and discontinued eventually (Verweij et al., 2000). 
More recently, a specific N-type voltage-gated calcium channel blocker SNX-185 
injected into the rats’ hippocampus reduced neuronal injury 24h after TBI, increased 
neuronal survival at 42 days , and improved behavioral outcomes in the beam walk 
and Morris water maze (Lee et al., 2004). This may seem promising with no side 
effects but application in TBI patients is difficult. 
 
1.2.4    Free radical scavengers 
After TBI, there is an imbalance between production of ROS and amount of 
antioxidant reserves, causing lipid peroxidation of the cell membrane with subsequent 
loss of membrane integrity, protein dysfunction and DNA damage (Tyurin et al., 
2000). Free radical scavengers have antioxidant effects which are neuroprotective in 
experimental TBI, but they have not shown efficacy in the clinical setting (Narayan et 
al., 2002). Clinical trials using high dose corticosteroids like dexamethasone, 
methylprednisolone (Alderson and Roberts, 2005) and the lipid peroxidation inhibitor 
Tirilazad (Narayan et al., 2002) have been disappointing, as they result in a higher 
28 
 
incidence of mortality and severe disability in people with TBI. Administration of 
SOD consistently improved cerebral blood flow post-injury across several TBI 
models (Cherian and Robertson, 2003; DeWitt et al., 1997; Muir et al., 1995),  
improved neurological recovery, attenuated cerebral edema and improved survival 
following TBI in the rat (Levasseur et al., 1989; Michelson et al., 1988). Polyethylene 
glycol-conjugated superoxide dismutase (PEG-SOD) improved BBB penetration 
following experimental TBI (Yoshida et al., 1992) and reduced neurological motor 
deficits in LFP brain injury in rats (Hamm et al., 1996). 
 
Nitric oxide (NO) is synthesized from L-arginine by at least three isoforms of nitric 
oxide synthase (NOS); neuronal NOS (nNOS; type I), inducible NOS (iNOS; type II) 
and endothelial NOS (eNOS; type III). Evidence suggests that eNOS activity is 
neuroprotective after acute brain injury, whereas iNOS and nNOS activity may be 
detrimental (Iadecola, 1997). Post-injury treatment with a selective inhibitor of nNOS, 
BN 80933, shows improved neurological outcome in mice subjected to weight drop 
injury (Chabrier et al., 1999). Furthermore, pretreatment with a relatively specific 
inhibitor of nNOS, 3-bromo-7-nitroindazole (7-NI) significantly reduced the 
contusion volume in rats subjected to FPI (Wada et al., 1998). The iNOS inhibitor 
aminoguanidine shows a marked reduction of lesion volume and neuronal cell loss, 
with a concomitant improvement in neurological motor performance and grip strength 
after FPI in rats (Lu et al., 2003). Lubelozole, a NOS pathway inhibitor with unknown 
mechanism, failed to improve cerebral edema or contusion volume following 




Although many agents have been studied, PEG-SOD and Lubelozole have been 
demonstrated to be the only agents showing efficacy in either Phase II or III clinical 
trials (Marklund et al., 2006). PEG-SOD helps to scavenge superoxide radicals while 
Lubelozole is a NOS inhibitor. Further investigations on the efficacy of free radical 
scavengers for the treatment of TBI are warranted, in terms of dosage and therapeutic 
window for treatment. 
 
1.2.5    Anti-inflammatory agents 
Secondary injury after TBI triggers an acute inflammatory response which leads to the 
breakdown of BBB, edema formation, infiltration of peripheral blood cells and release 
of cytokines (Morganti-Kossmann et al., 2002). Some compounds which reduce the 
damage from these processes include inhibitors of cyclooxygenase (COX), cytokines 
and bradykinin-specific β2 receptors (Marklund et al., 2006). 
 
COX enzyme exists in three isoforms, COX-1, COX-2 and COX-3 which catalyze the 
formation of inflammatory prostaglandins (PGs) from arachidonic acid (AA) released 
following TBI. COX-1 is constitutively expressed in most tissues whereas COX-2 is 
lowly expressed in neurons and glial cells in certain regions of the brain. Non-
selective COX inhibitors like indomethacin have shown to improve neurological 
function and decrease mortality following experimental TBI (Kim et al., 1989). 
However, it was found to reduce cerebral blood flow (CBF) in patients with head 
injury and is not recommended for treatment (Dahl et al., 1996). 
 
Cytokines are polypeptides mediating inflammation, regulating cell growth and 
differentiation. They consist of tumour necrosis factor (TNF), interleukins (IL), 
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interferons and growth factors consisting of nerve growth factor (NGF) and 
transforming growth factor-a (TGF-a) (Morganti-Kossman et al., 1997). TNF-α, IL-6, 
IL-1 and IL-18 are important mediators of neuroinflammation; they are produced by 
astrocytes, macrophage/microglial cells, neurons and endothelial cells in the CNS in 
response to acute brain injury (Shohami et al., 1994a; Taupin et al., 1993; Yatsiv et 
al., 2002). Pentoxifylline, a compound which inhibits the production and activity of 
TNF-α and TNF- α binding protein (TNFBP) attenuated  both neurological motor 
deficits and edema after closed head injury (CHI) in rats (Shohami et al., 1996). A 
study using monoclonal antibodies to inhibit TNF-α and  IL-6 in the first hour after 
LFP brain injury showed no improvement in neurological and cognitive function 
(Marklund et al., 2005). The term IL-1 refers to three molecules (IL-1 a, IL-1b and 
IL-1 receptor antagonist (IL-1ra)). Since IL-1 has been associated with cognitive 
deficits, neurodegeneration and apoptosis (Friedlander et al., 1996; Rothwell and 
Luheshi, 2000), antagonism of IL-1 with the IL-1 receptor antagonists may have 
neuroprotective effects in the injured brain. There are reports on  recombinant human 
(rh)IL-1ra administered after LFP brain injury, resulting in improved cognitive 
function and reduced cortical lesion volume (Sanderson et al., 1999; Toulmond and 
Rothwell, 1995). Although many of these reports have demonstrated promising 
effects of cytokine inhibition, a clinically useful cytokine inhibitor is still not 
available, as cytokines seem to have dual roles in the injury process post-trauma. 
 
The activation of the kallikrein-kinin system in TBI produces endogenous 
inflammatory agent bradykinin which acts through receptors on neuronal, glial and 
endothelial cells to release cytokines, nitric oxide (NO), free radicals and excitatory 
amino acids (EAA) (Zausinger et al., 2002). This has led to the development of 
31 
 
specific bradykinin B2 receptor antagonists such as Bradycor (CP-0127), which is 
found to be neuroprotective in severe brain injury patients in a phase II clinical trial 
(Marmarou et al., 1999). Another non-peptide B2 receptor antagonist (LF-16-
0687Ms) has only shown to reduce TBI-induced vasogenic brain edema in rats 
(Stover et al., 2000). 
 
In conclusion, inhibition of the post-traumatic inflammatory cascade continues to be a 
viable treatment option. However, the development of clinically-relevant 
pharmaceutical compounds will need to take into consideration that inflammatory 
processes can be beneficial or detrimental at different times point after injury. 
 
1.2.6    Apoptosis and caspase inhibitors 
As discussed earlier in the introduction, apoptotic cell death of neurons and glia 
contributes to the overall pathology of clinical and experimental TBI. Although 
activation of numerous different caspases have been observed in TBI, the activation 
of apoptosis executioner caspase-3 is a consistent finding across many experimental 
TBI models (Eldadah and Faden, 2000; Raghupathi et al., 2000). Potential targets for 
drug development to treat the sequelae of TBI will include inhibitors of apoptotic 
proteins, especially caspase-3 inhibitor. Several caspase inhibitors of varying 
specificity have been tested in models of acute brain injury.  
 
Some ketones are potential caspase inhibitors because of their reversible interaction 
with the cysteine residue of the active site and their stability in vivo (Lopez-
Hernandez et al., 2003). N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (z-
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VADfmk), which is a general caspase inhibitor, can attenuate both motor and 
cognitive effects following LFP brain injury in rats (Knoblach et al., 2002). It can also 
reduce lesion volume and reduce free radical production following murine weight 
drop TBI (Fink et al., 1999). Administration of the caspase-3-specific N-
benzyloxycarbonyl-Asp-Glu-Val-Asp fluoromethyl ketone (z-DEVDfmk) reduced 
contusion size and CA3 hippocampal cell loss but had no effect on motor and 
cognitive outcomes (Clark et al., 2000). Apoptosis involves the delayed onset of 
cellular deterioration, this offers a potential window of opportunity for therapeutic 
(anti-apoptotic) interventions. The role for anti-apoptotic compounds in TBI is still 
controversial, and to date, more preclinical research is necessary before attempting to 
use in treatment of human TBI.  
 
1.2.7    Neurotrophic factors 
Neurotrophins are secreted peptides required for the development, maintenance and 
regeneration of the CNS. The family of neurotrophins consists of NGF, brain derived 
neurotrophic factor (BDNF), neurotrophin 3 (NT3), NT4/5 and glial cell-derived 
neurotrophic factor (GDNF). The upregulation of neurotrophic factors after TBI 
suggests an attempt for endogenous neuroprotection, therefore exogenous 
administration of these growth factors can act as potential therapeutic agents for the 
treatment of TBI. The beneficial effect of NGF may be related to its ability to 
attenuate cognitive deficits and apoptotic cell death. 
 
At 24 hours post-injury, transplantation of cells genetically engineered to over express 
NGF improved cognitive function (Philips et al., 2001; Watson et al., 2003) and 
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reduced hippocampal cell death (Philips et al., 2001) in rats and mice. NGF appears to 
be a potential candidate for treatment, but it causes allodynia and hyperalgesia which 
limits its use in humans (Svensson et al., 2003). There are several reports showing the 
effects of NT-4/5 on neuronal survival and regeneration both in vitro and in vivo in 
other experimental models of CNS injury (Conte et al., 2003). This implies that 
NT4/5 could be involved in repair-regeneration mechanisms and therefore used as a 
potential therapeutic tool for the treatment of TBI. When GDNF was 
intracerebroventricular (ICV) infused immediately post-injury for 7 days following 
TBI in rats, a significant decrease in CA2 and CA3 cell loss was observed (Kim et al., 
2001). On the other hand, BDNF showed no improvement in cognitive function or 
histological outcome after LFP brain injury in rats (Blaha et al., 2000), while no 
studies to date have addressed the potential therapeutic effects of NT3 following TBI 
(Marklund et al., 2006). Based on the information above, further evaluation for NGF, 
NT4/5 and GDNF is recommended. 
  
Currently, a small molecule analog of Glypromate® [Glycine-Proline-Glutamate], 
NNZ-2566 which is derived from insulin-like growth factor 1 (IGF-1) is in phase II 
clinical trials. It is developed for acute and recovery phase treatment of TBI. 
Experimental studies in animals have shown that it can reduce non-convulsive 
seizures and this can be easily observed to assess the outcome of TBI (Jain, 2008).  
 
In conclusion, neurotrophic factors continue to be a treatment option with vast clinical 
potential, provided that more data on the route of administration, dose, time-window 
for treatment and possible adverse side effects are available. They are the only agents 
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which stimulate neuronal growth and differentiation as compared to others which only 
reduce the extent of damage. 
 
1.2.8    Poly(ADP-ribose) polymerase (PARP) inhibitors 
PARP which is a DNA base excision repair enzyme, binds to DNA strand breaks and 
utilizes nicotinamide adenine dinucleotide (NAD) as a substrate. Since consumption 
of NAD may be deleterious to recovery in CNS injury, the role of PARP inhibitors 
may be important. PARP is activated at 30 minutes post LFP brain injury and this 
indicates DNA damage (Besson et al., 2003; LaPlaca et al., 1999). Pre-treatment with 
two potent PARP inhibitors PJ34 and INO-001, reduced lesion volume and 
neurological motor deficits following LFP brain injury in rats (Besson et al., 2005). 
Inhibition of PARP shows promising preclinical efficacy in TBI although time-
window for treatment and outcome measures need to be evaluated more extensively. 
 
1.2.9    Multipotential drugs 
Multipotential drugs are drugs which simultaneously target several injury factors in 
TBI. They are likely to have successful therapeutic intervention as TBI involves 
several secondary injury pathways. The pharmacological agents which have 
promising effects after experimental TBI and currently reviewed in clinical trials 
include statins, progesterone and cyclosporine A (Loane and Faden, 2010). Statins are 
commonly known to inhibit cholesterol biosynthesis, but recently it has been reported 
that they can act as neuroprotective agents (Wible and Laskowitz, 2010). In TBI 
models, statins protect cortical neurons from excitotoxic death (Zacco et al., 2003), 
improve survival of neurons (Wang et al., 2007) and decrease apoptosis after trauma 
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(Wu et al., 2008). They have also been shown to limit production of inflammatory 
mediators, glial cell activation and cerebral edema while increasing BBB integrity 
(Chen et al., 2009; Wang et al., 2007). Importantly, statins are well tolerated, have 
well-defined side effects, easily administered and monitored in patients (Tseng et al., 
2005). Progesterone is a neurosteroid whose receptors are expressed in the CNS of 
both males and females (Camacho-Arroyo et al., 1994). Progesterone attenuates 
glutamate excitotoxicity (Smith, 1991), modulates apoptotic pathways (Yao et al., 
2005), reduces membrane lipid peroxidation (Roof et al., 1997), limits inflammation 
(Pan et al., 2007) and edema (O'Connor et al., 2007) after injury. However, a 
clinically relevant therapeutic window for progesterone still needs to be established 
(Gibson et al., 2008). There are significant impairments of aerobic metabolism early 
after TBI. Cyclosporine A (CsA) helps to preserve mitochondrial function (Sullivan et 
al., 1999), therefore reducing axonal damage (Okonkwo and Povlishock, 1999) and 
lesion size (Sullivan et al., 2000) in experimental TBI. CsA has a long therapeutic 
window but it shows relatively poor brain penetration, has a biphasic drug-response 
curve and adverse effects on the immune system after prolonged use (Margulies and 
Hicks, 2009). 
 
1.2.10    Herbal Medicines for TBI 
Despite improvements in medical and surgical treatment for primary outcomes of 
TBI, there are currently no approved neuroprotective agents available to counteract 
secondary damage in the injured brain or to stimulate its repair and recovery. 
Furthermore, there is no single agent which is able to target the complete pathology of 
TBI and its complications, because each of them has only one or a few specific 
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pharmacological effect. It is reported that natural products act as antioxidants which 
can enhance the activity of endogenous antioxidants, prevent free radical generation 
and neutralize free radicals by non-enzymatic mechanisms (Zhu et al., 2004).  The use 
of natural alternative medicine can be an option to solve the problem of high 
medication cost and side effects of the medication. Natural alternative medicine can 
also improve the general health condition since they are holistic. 
 
Currently, only few Chinese herbs have been shown to improve the outcome of TBI. 
For example, Rhubarb reduces intracranial pressure in severe brain injury (Gu et al., 
2000). The safflower plant Carthamus tinctorius improves mitochondrial and 
antioxidant activities and also has antithrombotic effects in TBI (Bie et al., 2010). 
More recently, osthole isolated from Cnidium monnieri has been shown to have 
antioxidative and antiapoptotic effects against TBI (He et al., 2012).  
 
In this study, the therapeutic effects of HL on TBI will be investigated. According to 
literature, the protective effects of HL are currently limited to acute myocardial 
infarction (AMI) and stroke but not in TBI. Interestingly, it was reported that early 
ischemic episodes occur after TBI in addition to the primary mechanical damage 
(Leker and Shohami, 2002). Common pathological and protective processes, as well 
as the common response to neuroprotective strategies in TBI, AMI and stroke suggest 
that similar drugs could be effective against these processes. Thus, we want to 
investigate if HL could have neuroprotective effects after TBI, by decreasing 




1.3:    Traditional Chinese Medicine (TCM) 
 
Recently, there has been intense interest on the antioxidant properties of natural 
products. In particular, TCM have become hot topics for life sciences researchers as 
many of them have been reported to have antioxidant effects.  
 
TCM acts as antioxidants by enhancing the activity of original natural antioxidants, 
preventing free radical  generation, and neutralizing free radicals through 
nonenzymatic mechanisms (Zhu et al., 2004). Since free radicals contribute to a wide 
range of damage in various diseases, such as cardiovascular diseases, 
neurodegenerative disorders and even cancers, antioxidant properties of TCM provide 
a new insight into treatment or prevention of these diseases. However, our 
understanding of the scientific principles of herbal drugs is still insufficient, resulting 
in the limitation of their wide spread use in patients, especially in western societies. 
 
A brief review on the antioxidative properties of TCM studied in our laboratory and 
their therapeutic potential on some disease models will be discussed in this section. 
 
1.3.1    Herba leonuri and pHL  
Herba leonuri (HL), also named “Chinese Motherwort”, belongs to the Labiatae 
family in the plant kingdom (Figure 2-5). The major known ingredients in HL include 
stachydrine, leonuridine, leonurinin, benzenoid (Leo), phenylpropanoid, 
monoterpenoid, diterpenoid, tetraterpenoid, sesquiterpenoid, saponin, proteins such as 
cycloleonurinin, cycloleonuripeptide A, B, C, D and lipids such as linoleic acid and  
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lauric acid. It also contains large amounts of potassium and vitamins (Dan and 
Andrew, 1993; Zhu et al., 2004). 
 
Its pharmaceutical name is Herba leonuri Heterophylli, and the botanical name is 
Leonurus heterophyllus sweet. HL is harvested when the stems and leaves are 
luxuriant before or at the beginning of the flowering season. Harvested stems and 
leaves are then dried under the sun. In terms of traditional Chinese medicine, it is 
known as the “mother-benefiting herb”. It is prescribed during menstruation and child 
delivery in gynecology. In terms of Chinese medicine, it has bitter and pungent tastes. 
Therefore, it will act on the liver, pericardium and urinary bladder channels to 
promote blood circulation, by removing blood stasis and qi stagnation when entering 
the blood system. It can also clear heat and toxic substances and subdue swelling due 





Figure 1-5: HL (Chinese Motherwort) [Adapted from (Zhu et al., 2004)] 
 
Studies have been done to investigate the effect of HL on cardiac protection. It is 
reported to protect the subcellular structure of the myocardium, improve ischemic 
electrocardiography (ECG), decrease blood hyperviscosity, increase coronary flow 
and microcirculation, decrease heart rate, reduce the release of creatine kinase, 
asparatate amino transferase, and L-lactate dehydrogenase in the plasma and finally 
reduce the infarct area (Pang et al., 2001; Zou et al., 1989). The underlying 
mechanisms are yet to be elucidated. 
 
Importantly, HL is demonstrated to have antioxidant properties as shown by its strong 
superoxide-scavenging ability measured by an electron spin resonance (ESR) spin-
trapping technique in vitro (Liu et al., 2001). An early study reported that HL exerts 
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protective effects on ischemic heart diseases at least through its antioxidant properties 
(Sun et al., 2002). 
 
The progression of HL studies is the discovery of purified HL with 5 known 
compounds. The purified HL, also named Kardigen (Herbatis Pte. Ltd., Singapore) 
was analyzed by LC (liquid chromatography)-ESI (electrospray ionization)-MS (mass 
spectrometry) system (API 365 LC-MS system, Applied Biosystems, USA) (Sun et 
al., 2005). The extract consists mainly of Leo (C14H21N3O5), Stachydrine (C7H13NO2), 
Quercetin (C15H10O7), Apigenin(C15H10O5) and Kaempferol (C15H10O6) (Figure 2-6). 
Most importantly, pHL has also shown the effects of scavenging free radicals and 
inhibiting the formation of reactive oxygen species in vitro, indicating that pHL may 




Figure 1-6: The 5 known compounds from pHL [Adapted from(Loh et al., 2009)] 
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Our group reported that pHL has cardioprotective effects on ischemic myocardium 
(Sun et al., 2005). pHL (400 mg/kg/day) was administered orally once daily to the rats 
subjected to myocardial infarction (MI) from 1 week before MI surgery and 3 weeks 
after the surgery. We reported for the first time that pHL does have cardioprotective 
effect through antioxidant effects both in vitro and in vivo, by preserving the activities 
of SOD and GPx. pHL also ameliorated oxidative stress associated with MI as shown 
by the reduction in the formation of malondialdehyde (MDA) (Sun et al., 2005). 
 
1.3.2    Leo 
Leo is an alkaloid present in HL (Kong et al., 1976). It is also one of the compounds 
obtained after purification of HL as shown in Figure 1-6. It was reported to have 
uterotonic action and anti-platelet aggregation activities (Kuang et al., 1988). It is also 
an effective inhibitor of vascular smooth muscle tone, probably through inhibition of 
Ca2+ influx and the release of extracellular Ca2+ (Chen and Kwan, 2001).  
 
From our previous studies, we demonstrated that Leo confers cardioprotective effect 
as it is shown to attenuate apoptosis after chronic myocardial ischemia. It can activate 
the phosphoinositide3-kinase (PI3K)/Akt signaling pathway. Akt phosphorylation 
increased after treatment both in vivo and in vitro. As a result, mRNA and protein 
expression of vascular endothelial growth factor (VEGF) increased. The protein 
expression of hypoxia Inducible Factor-1 alpha (HIF-1α) and survivin also increased 
(Liu et al., 2010a; Liu et al., 2010b). Both gene and protein expression of Bcl-2 were 
up-regulated and Bax was down-regulated in vivo (Liu et al., 2010a; Liu et al., 
2010b). In addition, gene expression of manganese-SOD (Mn-SOD) and SOD activity 
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increased while lipid peroxidation decreased in AMI treatment group (Liu et al., 
2010b).  
 
Furthermore, Liu et al., (2009a) did in vitro studies of myocardial infarction (MI) by 
exposing cardiomyocytes and cardiac muscle cells to hypoxia. On the other hand, Xin 
et al., (2009)  treated cardiac muscle cells with doxorubicin to induce cardio toxicity. 
After treatment with Leo, the infarct area caused by MI reduced (Liu et al., 2009b). 
Pro-apoptotic genes Bax (Liu et al., 2009a; Liu et al., 2009b; Xin et al., 2009) and Fas 
(Liu et al., 2009b) were down-regulated and anti-apoptotic genes Bcl-2 (Liu et al., 
2009a; Liu et al., 2009b; Xin et al., 2009) and Bcl-xL (Liu et al., 2009b) were up-
regulated. Correspondingly, Bcl-2 protein level increased and Bax protein level 
decreased (Liu et al., 2009a; Liu et al., 2009b; Xin et al., 2009). Leo increased the 
activity of total SOD and CAT and suppressed lipid peroxidation (Liu et al., 2009b). 
Intracellular Ca2+ level (Liu et al., 2009a; Liu et al., 2009b; Xin et al., 2009) and 
MDA level were also lowered (Liu et al., 2009b; Xin et al., 2009). Since Leo has 
shown protective effects through anti-oxidative and anti-apoptotic mechanisms in the 

































2.1.1    Test compounds (pHL and Leo) 
2.1.1.1    pHL 
The raw material of HL originated from Sichuan Province (China). pHL powder is 
commercially available in Singapore and is supplied by Herbatitis Pte. Ltd.  
 
 
Figure 2-1: Mass spectrum of pHL 
 
2.1.1.2    Leo 
Leo (molecular weight: 333) is synthesized from syringic acid by carbonylation, 
reaction with thionyl chloride (SOCl2) and the Gabriel reaction, as previously 
described (Zhu et al., 2005). Leo was confirmed to have 99% purity by high 






2.1.2    Animals 
In this study, 60 healthy male Wistar rats weighing 300-350g were obtained from the 
Centre for Animal Resources (NUS). They were allowed to acclimatize to conditions 
in the Animal Holding Unit (AHU), Defence Science Organisation (DSO) National 
Laboratories  where they were housed throughout the experiment on a 12-hour 
light/dark cycle. Water and feeds were available to the animals ad libitum. The 
Principles of Laboratory Animal Care (NIH, 1985) were followed throughout the 
duration of experiment. The experimental protocol for animal study was approved by 
NUS Institutional Animal Care and Use Committee (IACUC) and DSO National 
Laboratories Institutional Animal Care and Use Committee (DSO IACUC). 
2.1.3    Chemicals 
All chemicals and reagents used in this study were supplied from Sigma-Aldrich, Inc. 
(St.Louis, MO, USA), unless otherwise specified. 
 
2.2:    Methods 
 
2.2.1    Experimental protocol I 
2.2.1.1    Objectives 
Generally, a pilot study to investigate the therapeutic effects of pHL on rats with TBI. 
In this study, we would like to illustrate: 
1. The effect of pHL on TBI-induced rats in terms of brain morphology. 
2. The antioxidant and anti-apoptosis capacity of pHL on TBI-induced rats. 
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2.2.1.2    Experimental design 
The experimental design is illustrated in Figure 2-1. A total of 60 male Wistar rats 
weighing 300-350g were randomly divided into three groups: sham-operated group 
with water treatment (Con), TBI group with water treatment (TBI/Vehicle) and TBI 
group with pHL treatment (400mg/kg/day) (TBI/pHL). This dose of pHL was selected 
based on data from previous ischemia studies in the lab (Loh et al., 2009). The pHL 
extract was dissolved in water. Then, it was administered orally once daily after TBI 
and sacrificed after 7 days for sample collection. Sham rats received anesthesia and 
surgery but were not subjected to trauma. Experiments performed include H&E 
staining, TUNEL staining, immunohistochemical staining, antioxidant assays and 
western blot analysis. 
 
Sham Vehicle TBI + pHL
TBI/ Sham-operated surgery











Western  blot 
analysis
 





2.2.2    Experimental protocol II 
2.2.2.1    Objectives 
In Experiment II, a key compound of pHL (Leo) was targeted to identify if it is 
one of the active ingredients of pHL for neuroprotection. In this study, we would like 
to illustrate: 
1. The effects of Leo on TBI-induced rats act through antioxidant and anti-apoptotic 
mechanisms. 
2. The difference in effects of pHL and Leo on the studied mechanisms. 
2.2.2.2    Experimental design 
The experimental design is illustrated in Figure 2-2. A total of 60 male Wistar rats 
weighing 300-350g were randomly divided into three groups: sham-operated group 
with water treatment (Con), TBI group with water treatment (TBI/Vehicle) and TBI 
group with Leo treatment (60mg/kg/day) (TBI/Leo). This dose of Leo was selected 
based on data from previous ischemia studies in the lab (Loh et al., 2010). Leo 
powder was dissolved in water by sonication. Then, it was administered orally once 
daily after TBI and sacrificed after 7 days for sample collection. Sham-operated  rats 
received anesthesia and surgery but were not subjected to trauma treatment. 




Sham Vehicle TBI + Leo
TBI/ Sham-operated surgery





Western  blot 
analysis
 




2.2.3    Experimental protocol III 
2.2.3.1    Objectives 
In Experiment III, the effects of pHL and Leo in the treatment of TBI were compared. 
In this study, we would like to illustrate: 








2.2.3.2    Experimental design 
Compare the free radical scavenging activities of pHL and Leo using DPPH (2,2-
diphenyl-1-picrylhydrazyl) antioxidant assay and relate this to differences (if any) in 
antioxidant and anti-apoptotic effects. 
 
2.2.4    Experimental techniques 
2.2.4.1    Lateral fluid-percussive brain injury (FPI) 
The rats were anesthetized with ketamine/xylazine mixture (0.1ml/100g, i.p.), 
ventilated and placed in a stereotaxic frame. A 5mm craniotomy was made over the 
right parietal cortex (2mm lateral to the saggital suture and 3mm posterior to the 
coronal suture), leaving the dura intact. A hollow female Luer Lock fitting was fixed 
rigidly with dental cement over the craniotomy. Brain injury was performed using a 
lateral fluid percussion model as previously described (McIntosh et al., 1989), in 
which brief displacement and deformation of the brain resulted from the rapid 
epidural injection of saline into the closed cranial cavity. Animals were subjected to a 
3.7atm pressure pulse which produced severe tissue damage in the  ipsilateral cerebral 
cortex and hippocampus (Prins et al., 1996). During the surgical procedure, the 
animal’s body temperature was monitored with a rectal thermometer and maintained 
at 37oC. After surgery, the animals were placed in an incubator at 37oC until they 
regained consciousness. They were then returned to their home cages and given food 






2.2.4.2    Hematoxylin and Eosin staining 
The animals were euthanized with  an overdose of pentobarbital (i.p.) and 
intracardially perfused with Ringer’s solution (85g NaCl, 2.5g KCl, 3g CaCl2, 2g 
NaHCO3 in 10 litres of deionized water)  followed by 4% paraformaldehyde (PFA). 
After fixation, the brains were removed and then postfixed in 4% PFA for at least one 
day. The brains were paraffin-embedded and coronally sectioned on a microtome 
(Leica, RM2165, Bensheim, Germany). Each section was cut into 6µm thick slices 
mounted on poly-L-lysine-coated slides (Thermo Fisher Scientific Inc., USA) and 
dried overnight on a slide warmer (Thermo Fisher Scientific Inc., USA). Following 
this, the sections were deparrafinized, hydrated in a series of decreasing concentration 
of ethanol, stained in hematoxylin and eosin (H&E) reagent (Thermo Fisher Scientific 
Inc., USA), dehydrated in a series of increasing concentration of ethanol, immersed in 
two changes of histoclear and finally cover-slipped. Hematoxylin stains nuclear 
substances blue to black while eosin stains cytoplasm pink, therefore general 
structural features of the tissue can be displayed. The CA1, CA2 and CA3 regions of 
the right hippocampus underlying the area of contusion were examined and evaluated 
in random order under blindfold conditions with a standard light microscope 
(Olympus, DP72, Tokyo, Japan). 
 
2.2.4.3    TUNEL (TdT-mediated dUTP Nick-End Labeling) assay  
Apoptosis was measured with terminal deoxynucleotidyl transferase-mediated dUTP 
nick end labelling (TUNEL) staining of brain slices (sectioned at 6µm thickness) 
using the DeadEnd™ Fluorometric TUNEL System (Promega, Madison, WI, USA). 
Apoptosis-induced nuclear DNA fragmentation results in localized green fluorescence 
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within the nucleus of apoptotic cells which can be detected by fluorescence 
microscopy. The slides were mounted with Fluoroshield with DAPI (4',6-diamidino-
2-phenylindole) (Sigma Aldrich Inc., St. Louis, MO, USA) to stain the nucleus of 
cells. After drying the slides overnight in the hood, they were viewed and 
photographed using a fluorescent microscope (Olympus, BX51, USA) with a standard 
fluorescin filter to view green fluorescence at 520±20nm. 
 
2.2.4.4    Immunohistochemical staining 
Immunohistochemical detection of NeuN-, GFAP- and Cd11b-stained cells was done 
on 6µM paraffin sections. First, the sections were deparrafinized, hydrated in a series 
of decreasing concentration of ethanol and immersed in running water. Antigen 
retrieval was done by microwaving slides in Tris EDTA buffer (pH9.0). Non-specific 
binding sites were blocked with 1% bovine serum albumin (BSA) in tris-
(hydroxymethyl)-aminomethane buffered saline with 0.1% Tween20 (TBST). Excess 
moisture around the sections was wiped off by paper towels before primary antibody 
was added. Sections were incubated with anti-NeuN (1:200) (Santa Cruz, USA), anti-
GFAP (1:400) (Millipore, USA) or anti-Cd11b (1:100) (AbSerotec, USA) primary 
antibodies overnight at 4oC. The next day, primary antibodies were visualized using 
goat anti-mouse Alexa Fluor 555 (Life Technologies, USA) secondary antibody for 
one hour, washed with TBST and mounted with DAPI (Sigma Aldrich Inc., St. Louis, 
MO, USA). After drying overnight in the hood, sections were analyzed on an 
Olympus fluorescence microscope (Olympus, BX51, USA). Three adjacent brain 
sections at 100µM intervals and within the approximate center of the contusion were 
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selected for data analysis. Positively stained cells were counted at 200X magnification 
in four fields randomly chosen from each brain section. 
 
2.2.4.5    Biochemical analysis 
The rats were euthanized with an overdose of pentobarbital (i.p.) one week after TBI 
and the brains were removed immediately. The cortex surrounding the wound was 
separated on ice, rinsed with phosphate buffer saline (PBS), pH 7.4 and stored at -
80oC. The tissues were homogenized with their respective assay buffers to obtain 10% 
(w/v) homogenates, which were then centrifuged at 10,000 g, 4 °C for 15 min. The 
supernatants were collected, aliquoted and stored at −80 °C until time for analysis of 
enzyme activity. During analysis, the samples were further diluted 10X for SOD, 5X 
for CAT, GPx and GST, using the sample buffer provided in the commercial kits 
(Cayman Chemical Company, Ann Arbor, MI, USA). 
According to the manufacturer's instructions, total SOD activity was assayed by 
detecting superoxide radicals generated by xanthine oxidase and hypoxanthine. The 
reaction was monitored at 450 nm and one unit of SOD activity was defined as the 
amount of enzyme needed to exhibit 50% dismutation of superoxide radical. The 
CAT activity was assayed by measuring the reduction of hydrogen peroxide at 540 
nm and one unit was defined as the amount of enzyme that would cause the formation 
of 1.0 nmol of formaldehyde per minute at 25°C. The GPx activity was assayed by 
measuring the oxidation of NADPH to NADP+ at 340nm and one unit was defined as 
the amount of enzyme that would cause the oxidation of 1.0nmol of NADPH to 
NADP+ per minute at 25°C. The GST activity was assayed by measuring the 
conjugation of 1-chloro-2,4-dinitrobenzene (CDNB) with reduced glutathione at 
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340nm and one unit of enzyme will conjugate 1.0nmol of CDNB with reduced 
glutathione per minute at 25°C. All spectrophotometric readings were performed 
using a microplate spectrophotometer (Infinite M200, Tecan, Switzerland). All assays 
were conducted in triplicate. The tissue protein concentration was determined using 
the Bradford protein assay (Bradford, 1976), with purified BSA as a standard. 
 
2.2.4.6    Western blot analysis 
The cortex surrounding the contusion site and the hippocampus was harvested. The 
tissue specimens were immediately frozen in liquid nitrogen and later stored at -80oC. 
Tissues were homogenized in ice-cold buffer consisting of 20mM HEPES, 1.5mM 
MgCl2, 10mM KCL, 1mM EDTA, 1mM EGTA, 250mM sucrose, 0.1mM PMSF, 
1mM dithiothreitol (DTT) and protease inhibitor cocktail (Abcam, UK). The 
homogenates were centrifuged at 15,000 x g at 4oC for 30min and the supernatants 
were collected as protein samples. Quantification of the protein content in the samples 
was assayed with the Bradford protein assay (Bradford, 1976), with purified BSA as a 
standard. Equal protein concentrations were loaded and separated by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Subsequently, they were 
electro-transferred to nitrocellulose membranes (Bio-Rad, USA). Blotted protein was 
probed with anti-BAX, anti- Bcl-xL, anti-PARP, anti-caspase3, anti-SOD, anti-GPx, 
anti-GST(Santa Cruz, USA), anti-catalase (Merck, USA) and anti-GAPDH (Cell 
Signalling, USA). They were then probed with HRP-conjugated secondary anti-rabbit 
or anti-mouse antibodies (Santa Cruz,USA). Probed proteins were visualized with 
advanced ECL kit (Amersham, UK) and the intensities of bands were later quantified 
by ImageJ (NIH, USA). 
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2.2.4.7    DPPH (2,2-diphenyl-1-picrylhydrazyl) antioxidant assay 
DPPH was dissolved in methanol and mixed well to obtain 45μM  free radical DPPH• 
solution. Fresh DPPH• solution was prepared in the dark when the experiment was 
done. pHL and Leo were diluted with water to 20, 10, 5, 1 and 0.1mg/ml respectively. 
Vitamin C (VC) was diluted with water to 1, 0.5, 0.1, 0.01 and 0.001 mg/ml. 7ul of 
each sample or water was pipetted into a 96-well microplate. Next, 273ul of DPPH• 
solution was added and the absorbance at 517nm was monitored at regular intervals 
every 20 minutes and up to 120 minutes, using a microplate spectrophotometer 
(Infinite M200, Tecan, Switzerland). Each compound was tested in triplicates at five 
concentrations and the reaction involves a colour change from violet to yellow. 
 
The DPPH radical scavenging capacity can be calculated from the decrease in 
absorbance using the following equation:  
Elimination rate (% ) = (A0-A1)/A0, 
where A0 and A1 correspond to the absorbances of the radical (DPPH) at 517 nm in 
the absence and presence of antioxidant respectively.  
 
Then, the Effective Concentration (EC50) which refers to scavenging 50% DPPH 
radical can be obtained from the elimination graph. The EC 50 of each compound was 
divided by DPPH concentration, which is 17.16µg. The final EC 50 was expressed as: 






2.2.5    Statistical Analysis 
All values were presented as mean ± SEM (standard error mean). Data were analyzed 
using one-way analysis of variance (ANOVA) and Tukey test for post-hoc 






































3.1:    Results of experiment I: Cerebral protection of pHL extract on rats with 
TBI  
 
3.1.1    Pharmacological and functional outcome studies 
3.1.1.1    Effects of pHL on changes in general brain morphology following TBI 
The lesion area on the cortex for each treatment group after one week is shown in Fig. 
3-1. As expected, no lesion area was observed in the rats from the control group (Fig. 
3-1i). When the animal was subjected to right fluid percussion injury (FPI), the lesion 
was observed in the right cortex (Fig. 3-1ii). After treatment with pHL, the lesion area 
was reduced (Fig. 3-1iii). Results shown in Fig. 3-3 were taken 1week after TBI as 
there were no significant differences in morphology after treatment for 24h, 48h and 
72h following TBI (results not shown). Since there was significant histological 
outcome only at one week after TBI, this time point was chosen for all subsequent 
experiments. 
 
H&E staining of the cerebral cortex 
 
Figure 3-1: The lesion area (marked in black) on the cerebral cortex for each 
treatment group was observed by H&E staining under 1.25x magnification.  
From left (i) Control (Con); (ii) rats with TBI and treated with vehicle (TBI/Veh); (iii) 
rats with TBI and treated with 400mg/kg of pHL (TBI/pHL). 
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TUNEL staining was used to identify apoptotic cells. After staining, apoptotic cells 
exhibited strong, nuclear green fluorescence. Apoptosis was detected in the right 
cerebral cortex that was subjected to TBI (Fig. 3-2ii) while lesser apoptosis was 
detected in pHL-treated rats (Fig. 3-2iii). No apoptosis was seen in the sham-operated 
rats (Fig. 3-2i). 
 
TUNEL staining of the cerebral cortex  
(ii)(i) (iii)
 
Figure 3-2: Apoptotic staining in cerebral cortex for each treatment group was shown.  
Slides were viewed at 520±20 nm to detect nuclear green fluorescence. Scale bar= 
100µm.  
From left (i) Control (Con); (ii) rats with TBI and treated with vehicle (TBI/Veh); (iii) 










3.1.1.2    Effects of pHL on morphologic alterations in the hippocampus 
following TBI 
Fig. 3-3a shows the cell morphology in different regions of the hippocampus after 
TBI. In  the control group (Con), the morphology of neurons in brain tissue was 
normal. In the TBI plus vehicle (TBI/Veh) group, the neurons had shrunken 
cytoplasm, extensively dark pyknotic nuclei and vacuolization indicating tissue edema 
formation. In the TBI plus pHL-treated group (TBI/pHL), the intensity of traumatic 
changes was less than in the TBI/Veh group . In particular, the number of dark stained 
nuclei and distorted nerve cells was lowered by 39.5% in the CA1 region of the rat 













Effect of pHL on the cell morphology in the CA1, CA2 and CA3 regions of the 
rat hippocampus after TBI 
 
 
Figure 3-3(a): Representative light micrographs of H&E stained sections in rats of 
each experimental group. The enlarged image in the box denotes neurons undergoing 
degeneration. Scale bar= 100µm.  
Data represent means ± SEM for 6 rats per group. Control group (Con); rats with TBI 



































Figure 3-3(b): Quantitative assessment of the percentage of dark-stained nuclei and 
distorted nerve cells in each experimental group. 
Data represent means ± SEM for 6 rats per group. Control group (Con); rats with TBI 
and treated with vehicle (TBI/Veh) or 400mg/kg of pHL (TBI/pHL).  
*p<0.05, vs. sham; #p<0.05, vs. TBI; **p<0.01, vs. sham; ##p<0.01, vs. TBI 
 
 
3.1.1.3    Effects of pHL on neuronal loss, astrocyte and microglia gliosis 
following TBI 
Fig. 3-4(a) shows the NeuN-stained cells in different regions of the hippocampus after 
TBI. The NeuN-stained sections one week after TBI revealed a significant decrease in 
the number of neurons in the TBI/Veh group for all the regions indicated in the 
hippocampus. After treatment with pHL, there was a significant recovery in the 
number of neurons in the CA1, CA2 and CA3 regions by 124%, 59.8% and 55% 




Effect of pHL on the density of neurons in the CA1, CA2 and CA3 regions of the 
rat hippocampus after TBI 
 
 
Figure 3-4(a): Representative photomicrographs of NeuN-stained sections in rats of 
each experimental group. Scale bar= 100µm.  
Data represent means ± SEM for 6 rats per group. Control group (Con); rats with TBI 














































Figure 3-4(b): Quantitative assessment of the number of NeuN-stained cells in each 
experimental group. 
Data represent means ± SEM for 6 rats per group. Control group (Con); rats with TBI 
and treated with vehicle (TBI/Veh) or 400mg/kg of pHL (TBI/pHL).  
*p<0.05, vs. sham; #p<0.05, vs. TBI; **p<0.01, vs. sham; ##p<0.01, vs. TBI  
 
 
Fig. 3-5a shows the GFAP-stained cells in different regions of the hippocampus after 
TBI. In  the control group (Con), there were less GFAP-stained cells. The GFAP-
stained sections of brain taken one week after TBI revealed a significant increase in 
the number of GFAP-positive cells in the TBI/Veh group for all the regions indicated 
in the hippocampus. However, the number of GFAP-positive cells in the CA1, CA2 
and CA3 regions decreased significantly by 53.6%, 64.5% and 43.4% respectively in 
the TBI/pHL group (Fig. 3-5b). In particular, the GFAP-positive cells in the TBI/Veh 




Effect of pHL on the density of astrocytes in the CA1, CA2 and CA3 regions of 









Figure 3-5(a): Representative photomicrographs of GFAP-stained sections in rats of 
each experimental group. Scale bar= 100µm.  
Data represent means ± SEM for 6 rats per group. Control group (Con); rats with TBI 












































Figure 3-5(b): Quantitative assessment of the number of GFAP-stained cells in each 
experimental group. 
Data represent means ± SEM for 6 rats per group. Control group (Con); rats with TBI 
and treated with vehicle (TBI/Veh) or 400mg/kg of pHL (TBI/pHL).  
*p<0.05, vs. sham; #p<0.05, vs. TBI; **p<0.01, vs. sham; ##p<0.01, vs. TBI  
 
 
The cells stained with Cd11b in the CA1 region are shown in Fig. 3-6a. In  the control 
group (Con), there were few Cd11b-stained cells.  Cd11b-stained sections of brain 
taken one week after TBI showed a 75% reduction in the number of Cd11b-positive 
cells in the TBI/pHL group compared with the TBI/Veh group (Fig. 3-6b). In 
summary, pHL reduced neuronal loss, astrocyte and microglia gliosis in the 






Effect of pHL on the density of microglia in the CA1 region of the rat 
hippocampus after TBI 
 
 
Figure 3-6(a): Representative  photomicrographs of Cd11b-stained sections in rats of 































Figure 3-6(b): Quantitative assessment of the number of Cd11b-stained cells in each 
experimental group.  
Data represent means ± SEM for 6 rats per group. Control group (Con); rats with TBI 
and treated with vehicle (TBI/Veh) or 400mg/kg of pHL (TBI/pHL).  




3.1.2    Biochemical and molecular approaches 
3.1.2.1    Effects of pHL on the activities of SOD, CAT, GPx and GST in the 
cortex following TBI 
The values of SOD, CAT, GPx and GST activities are shown in Fig. 3-7 a, b, c and d 
respectively. It was observed that SOD activity decreased to 6.06 U/mg protein after 
TBI but restored to 13.6 U/mg protein in the TBI/pHL group. The activity of CAT 
decreased to 2.30 nmol/min/mg protein after TBI but restored to 2.88 nmol/min/mg 
protein in the TBI/pHL group. GPx activity decreased to 12.0 nmol/min/mg protein 
after TBI but restored to 15.1 nmol/min/mg protein after pHL treatment. The increase 
in SOD, CAT and GPx activities were significant in the TBI/pHL group. The 
administration of pHL showed protective effects via increase in SOD, CAT and GPx 
activities. The activity of each antioxidant enzyme corresponded with protein 
expression levels in the brain tissue. The activity of GST was not significantly 


















































































































Cont          TBI/Veh       TBI/pHL Cont          TBI/Veh       TBI/pHL






















Figure 3-7: Bar charts showing the activities of SOD (a), CAT (b), GPx (c) and GST 
(d) in each experimental group. Immunoblots shown on the top of each bar chart 
represent the expression levels for each antioxidant enzyme as compared to GAPDH. 
Data represent means ± SEM for 6 rats per group. Control group (Con); rats with TBI 
and treated with vehicle (TBI/Veh) or 400mg/kg of pHL (TBI/pHL).  








3.1.2.2    Effects of pHL treatment on neuronal apoptosis following TBI 
To investigate the protective effects of pHL against cell apoptosis induced by TBI, we 
examined the expressions of Bax (Bcl2-associated X protein), Bcl-xL (B-cell 
lymphoma-extra large), procaspase-3 and poly ADP-ribose polymerase (PARP) one 
week after TBI. Figure 3-8a shows the immunoblots for each of the proteins detected, 
with GAPDH as the loading control. As shown in figure 3-8b and d, the expressions 
of Bax and cleaved PARP increased significantly in the TBI group compared to the 
control group. However, with pHL treatment, the expressions of Bax and cleaved 
PARP decreased significantly by 37.7% and 41.5%, respectively. In contrast, the 
expression of Bcl-xL and procaspase-3 decreased significantly after TBI (Fig. 3-8c 
and e). After pHL treatment, the expressions of Bcl-xL and procaspase-3 were 













The expressions of Bax, Bcl-xL, PARP and procaspase-3 in the right 















Figure 3-8(a): Representative western-blot bands of Bax, Bcl-xL, cleaved PARP, 





Figure 3-8(b): Bar charts showing the expression levels of Bax (b), Bcl-xL (c), cleaved 
PARP (d) and procaspase-3 (e) in each experimental group after normalising with 
GAPDH. 
Data represent means ± SEM for 6 rats per group. Control group (Con); rats with TBI 
and treated with vehicle (TBI/Veh) or 400mg/kg of pHL (TBI/pHL).  
*p<0.05, vs. sham; #p<0.05, vs. TBI; **p<0.01, vs. sham; ##p<0.01, vs. TBI 
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3.2:    Results of experiment II: Leo protects rats with TBI through antioxidant 
and anti-apoptotic mechanisms 
 
3.2.1    Biochemical and molecular approaches 
3.2.1.1    Effects of Leo on the activities of SOD, CAT, GPx and GST in the 
cortex following TBI 
The values of SOD, CAT, GPx and GST activities are shown in Fig. 3-9 a, b, c and d 
respectively. It was observed that SOD activity decreased to 6.23 U/mg protein after 
TBI but restored to 9.77 U/mg protein in the TBI/Leo group. The activity of CAT 
decreased to 2.56 nmol/min/mg protein after TBI but restored to 2.78 nmol/min/mg 
protein in the TBI/pHL group. GPx activity decreased to 14.1 nmol/min/mg protein 
after TBI but restored to 15.8 nmol/min/mg protein after Leo treatment. The activity 
of GST also increased slightly after Leo treatment. In addition, the activity of each 
antioxidant enzyme corresponded with protein expression levels in the brain tissue. 
Among the treatment results, only the increase in SOD activity was significant. It is 
observed that the results of Leo treatment show the same trend but have less 
prominent effect as compared to pHL treatment. This might suggest that when Leo is 
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Figure 3-9: Bar charts showing the activities of SOD (a), CAT (b), GPx (c) and GST 
(d) in each experimental group. Immunoblots shown on the top of each bar chart 
represent the expression levels for each antioxidant enzyme. 
Data represent means ± SEM for 6 rats per group. Control group (Con); rats with TBI 
and treated with vehicle (TBI/Veh) or 60mg/kg of Leo (TBI/Leo).  









3.2.1.2    Effects of Leo treatment on neuronal apoptosis following TBI 
To investigate the protective effects of Leo against cell apoptosis induced by TBI, we 
examined the expressions of Bax (Bcl2-associated X protein), Bcl-xL (B-cell 
lymphoma-extra large), procaspase-3 and poly ADP-ribose polymerase (PARP) one 
week after TBI. Figure 3-10a shows the immunoblots for each of the proteins 
detected, with GAPDH as the loading control. As shown in Figure 3-10b and d, the 
expressions of Bax and cleaved PARP increased significantly in the TBI group 
compared to the control group. However, with Leo treatment, the expressions of Bax 
and cleaved PARP decreased significantly by 37.0% and 22.7%, respectively. In 
contrast, the expressions of Bcl-xL and procaspase-3 decreased significantly after TBI 
(Fig. 3-10c and e). After Leo treatment, the expressions of Bcl-xL and procaspase-3 
increased by 23.6% and 5.85%  significantly respectively. Although changes in 
expression of apoptotic proteins after Leo treatment were significant, there was still a 
big difference in effect when compared to changes after pHL treatment (Table 3-3). 
We can infer that pHL exerts a stronger anti-apoptotic effect which is possibly due to 











The expressions of Bax, Bcl-xL, PARP and procaspase-3 in the right hippocampus at 















Figure 3-10(a): Representative western-blot bands of Bax, Bcl-xL, cleaved PARP, 





































































































Figure 3-10(b): Bar charts showing the expression levels of Bax (b), Bcl-xL (c), 
cleaved PARP (d) and procaspase-3 (e) in each experimental group after normalising 
with GAPDH. 
Data represent means ± SEM for 6 rats per group. Control group (Con); rats with TBI 
and treated with vehicle (TBI/Veh) or 60mg/kg of Leo (TBI/Leo).  




3.3:    Investigating  antioxidant capacity of pHL and Leo in-vitro and also 
antioxidant and anti-apoptotic properties in TBI rats. 
 
3.3.1    Comparing the antioxidant effects  of pHL and Leo 
3.3.1.1    DPPH radical-scavenging activities of pHL, Leo and VC (positive 
control) 
 
The DPPH assay is widely used for assessment of an antioxidant compound and 
considered as one of the standard and easy colorimetric methods for the evaluation of 
antioxidant properties  of any compound. After obtaining the absorbance at 517nm 
versus time (mins) [not shown here], we can convert the data to show percentage of 
elimination of DPPH• radicals versus various concentrations of each compound 
(µg/ml) [Figure 3-11]. The graphs of VC, pHL and Leo are shown in Figure 3-11a, b 
and c respectively. VC is used as the positive control in this experiment since it has 
relatively strong antioxidant capacity. The EC50 ( half maximal effective 
concentration) refers to the concentration of test compound needed to scavenge 50% 
of initial DPPH• radicals, and can be determined from the graph. This value can be 








Graphs showing elimination rate of DPPH radicals against concentration of test 
compound used at different time points 
 
The assay was measured for 120 mins to obtain the maximal effective dose of each 















































































Figure 3-11: The graph for positive control VC in (a), pHL in (b) and Leo in (c).  
 
The EC50 is determined by the concentration of test compounds needed to inhibit 50% 










3.3.1.2    EC50 values of VC, pHL and Leo for DPPH assay 
 
Table 3-1: EC50 of VC, pHL and Leo for the eliminationof DPPH radicals 
Compound tested EC50 (µg of ext/µg of DPPH) 
VC (positive control) 0.10 ± 0.02 
pHL 3.50 ± 0.2 ** 
 
Leo 
Cannot be determined since inhibition 
rate did not reach 50% within the 
experimental time 
 
The EC50 is determined by the concentration of test compounds needed to eliminate 
50% of DPPH radicals from Fig.3-11 and divided by 17.16 as explained in 2.2.4.7 to 
get the final value  .  
 
Data represent means ± SEM for each compound for 3 assays per test compound. 
 
*p<0.05, vs. VC; **p<0.01, vs. VC 
 
 
As shown in Table 3-1, the EC50 of pHL is 3.50µg/µg of DPPH while the EC50  of Leo 
cannot be determined in this experiment. The elimination rate of Leo cannot reach 
50% even with maximum concentration and time. The EC50 value of pHL is 
approximately 35-fold higher than that of the positive control, VC (EC50=0.10µg of 
ext/µg of DPPH). Even though this EC50 value is significantly different from that of 
VC, pHL still demonstrated better DPPH radical-scavenging activity than Leo. This 
means that the amount of pHL needed to achieve the same in vitro antioxidant activity 
as VC might be reasonable and generally inexpensive. As for Leo, it is possible that a 
substantially higher concentration or longer duration is required to achieve the same 
in vitro effect as VC, a well-known synthetic antioxidant.  
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3.3.1.3    Comparison of the effects of pHL and Leo on the activities of SOD, 
CAT, GPx and GST in the cortex following TBI  
 
Table 3-2: The percentage increase in SOD, CAT, GPx and GST activities in 
TBI/pHL and TBI/Leo compared with TBI group  
Antioxidant enzyme pHL treatment after TBI 
(TBI/pHL) 
Leo treatment after TBI 
(TBI/Leo) 
SOD (% increase) 124 ± 4.92 ** 56.8 ± 4.95 
CAT (% increase) 25.3 ± 1.25 ** 8.83 ± 0.730 
GPx (% increase) 25.4 ± 2.12 * 12.1 ± 2.35 
GST (% increase) 7.68 ± 2.36  8.47 ± 2.28 
Data represent means ± SEM for 6 rats per group  
*p<0.05, vs. Leo; **p<0.01, vs. Leo 
 
The activity of different antioxidant enzymes were compared after TBI with either 
pHL or Leo treatment. This enabled us to make some observations on the antioxidant 
properties of pHL and Leo. From Table 3-2, it can be observed that the activities of 
SOD, CAT and GPx were generally higher in TBI/pHL than TBI/ Leo. As for the 
activity of GST, there was a slight increase of approximately 8% in both treatment 
groups, therefore no significant difference was noted. The biggest difference between 
the two groups was in the activity of SOD, followed by CAT and GPx. SOD activity 
in TBI/pHL increased by 124% and this was significantly higher than TBI/Leo by 
67.2%. The activity of CAT increased by 8.83% in TBI/Leo but it was significantly 
increased by another 16.5% in TBI/pHL. The activity of GPx increased by 12.1% in 
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TBI/Leo but it was significantly increased by another 13.3% in TBI/pHL. Since pHL 
can restore the endogenous antioxidant enzyme level more efficiently than Leo, it 
appears to have a better antioxidant effect against TBI. 
 
3.3.2    Comparing the anti-apoptotic effects of pHL and Leo 
3.3.2.1    Comparison of the effects of pHL and Leo on the expression of 
apoptosis-related proteins in the hippocampus following TBI     
 
Table 3-3: A summary of the percentage expression of Bax, BclXL, cleaved PARP and 
procaspase-3 in TBI/pHL and TBI/Leo compared with TBI group  
Protein expression pHL treatment after TBI 
(TBI/pHL) 
Leo treatment after TBI 
(TBI/Leo) 
Bax (% decrease) 37.7 ± 0.879  37.0 ± 1.99 
BclXL (% increase) 68.3 ± 3.79 * 23.6 ± 3.03 
Cleaved PARP (% decrease) 41.2 ± 1.82 ** 22.7 ± 1.41 
Procaspase-3 (% increase) 21.0 ± 1.32 ** 5.85 ± 1.04 
Data represent means ± SEM for 6 rats per group  
*p<0.05, vs. Leo; **p<0.01, vs. Leo 
 
 
The percentage expression of four different proteins involved in the apoptotic 
pathway was compared after TBI with either pHL or Leo treatment. This enables us to 
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make some observations on the anti-apoptotic properties of pHL and Leo. From Table 
3-3, it can be observed that the changes in expression of BclXL, cleaved PARP and 
procaspase-3 was significantly different between TBI/pHL and TBI/Leo. The increase 
in percentage expression of BclXL and procaspase-3 and decrease in percentage 
expression of cleaved PARP were more prominent in TBI/pHL than TBI/Leo. The 
percentage decrease in BAX expression for both treatment groups was similar, 
therefore no significant difference was noted. The highest percentage difference 
between the groups was in the expression of BclXL, followed by cleaved PARP and 
procaspase-3. The expression of BclXL increased by 68.3% and this was significantly 
higher than TBI/Leo by 44.7%. Similarly, the expression of procaspase-3 increased by 
another 15.2% when compared to TBI/Leo. On the other hand, the expression of 
cleaved PARP decreased by a further 18.5% when compared to TBI/Leo. Since pHL 
treatment can increase the expression of anti-apoptotic proteins (BclXL and 
procaspase-3) and decrease the expression of apoptotic protein (cleaved PARP) faster 























TBI involves a primary mechanical impact which causes skull fracture and damage to 
blood vessels and brain tissue (Gentleman et al., 1995b; Povlishock and Christman, 
1995a). This in turn triggers a cascade of events characterized by the activation of 
molecular and cellular responses which lead to secondary injury. These death-
promoting mechanisms include excitotoxicity, reactive oxygen species, inflammation 
and apoptosis (Leker and Shohami, 2002).  
 
There are several animal models of TBI for investigating the nature of human brain 
injury, but it is important to choose one which mimics closely the clinical sequelae of 
TBI in human. We have chosen to use the FPI model due to the excellent 
reproducibility of induced brain trauma. This model produces a mixed type of brain 
injury (Albert-Weissenberger and Sirén, 2010). The pathology caused by FPI includes 
cortical contusion, haemorrhage and a cytotoxic and/or vasogenic brain edema on the 
ipsilateral side (Cernak, 2005b; Morales et al., 2005a). The delayed progression of 
brain damage is accompanied by astrogliosis, diffuse axonal injury, inflammatory 
events, cortical spreading depression and neurodegeneration (Cernak, 2005b; Morales 
et al., 2005a; Yamaki et al., 1997). In particular, it produces severe tissue damage 
specific in the  ipsilateral cerebral cortex and hippocampus (Prins et al., 1996). 
 
In our study, we show for the first time that pHL and Leo can improve various 
parameters of cerebral damage mainly through anti-apoptotic and anti-oxidative 
mechanisms. It is beneficial to be able to target secondary events happening after TBI 
as these usually cause detrimental effects, leading to poor outcomes after TBI. pHL 
83 
 
reduces lesion area, neuronal loss and damage as well as astrocyte and microglia 
gliosis. It can reduce oxidative stress by increasing antioxidant enzymes SOD, CAT 
and GPx in the cortex after TBI. It also decreases the protein expression of BAX and 
PARP while increasing the protein expression of Bcl-xL and procaspase-3. As for 
Leo, it increases the SOD, CAT, GPx and GST activities in the brain tissue but only 
the increase in SOD was significant. Furthermore, the expression of BAX and PARP 
were significantly reduced while the expression of Bcl-xL and caspase-3 were 
significantly increased with Leo treatment compared to vehicle.  
 
An earlier study revealed that pHL can increase the level of antioxidant enzymes 
SOD, GPx and CAT in the heart of rats which have undergone myocardial infarction 
(Sun et al., 2005). Furthermore, a more recent study showed that pHL has significant 
neuroprotective effects involving antioxidative and anti-apoptotic effects in middle 
cerebral artery occlusion (MCAO) (Loh et al., 2009). Leo extracted from pHL has 
also been shown to reduce apoptosis, restore SOD and CAT levels and lower 
cytosolic Ca2+ in hypoxia and doxorubicin-induced apoptosis in cardiomyocytes (Liu 
et al., 2009a; Liu et al., 2009b; Xin et al., 2009). Leo also reduced apoptosis and 
restored SOD levels in rats with acute myocardial infarction (Liu et al., 2010b). 
Similarly, it has these effects in rats with stroke with an addition of restoring GPx 
levels (Loh et al., 2010). 
 
In our study, the findings in histological sections of neurons from the TBI group 
showed severe degenerative changes, shrunken cytoplasma, dark pyknotic nuclei and 
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vacuolization. These results correlate well with the literature (Kerman et al., 2012; 
Pun et al., 2011). The dark stained nuclei and the distorted nerve cells were fewer in 
TBI/pHL. In this group, the severity of degenerative changes in the cytoplasma and 
especially in the nuclei of cells was less than that in the TBI group. Our results also 
showed that astrocyte and microglia gliosis occured after TBI and was similar to what 
was observed by (Chio et al., 2010). These pathological changes may result in 
microglia scar which can hinder functional neuronal regeneration. In a review by 
(Silver and Miller, 2004), it was proposed that long-distance functional regeneration 
after TBI is possible if the inhibitory environment of the glial scar is absent. Indeed, 
as demonstrated  in our current results, TBI-induced gliosis of both astrocytes and 
microglia were significantly reduced by pHL therapy. Apparently, pHL might 
enhance actual functional neuronal regeneration via inhibiting glia scar formation 
during TBI. 
 
Oxidative stress contributes to progressive neuropathology in TBI. There are several 
antioxidant enzymes in neurons that decrease oxidative stress, including SOD, 
catalase, GPx and GST (Ho et al., 1997; Okado-Matsumoto and Fridovich, 2001; 
Wang et al., 2003; Xie et al., 2001). SOD represents the first line of defense against 
oxidative stress catalyzing the dismutation reaction of superoxide anion to hydrogen 
peroxide (McCord and Fridovich, 1969) , which is then converted to water by catalase 
and GPx (Shao et al., 2006). Glutathione transferase can detoxify aldehyde by-
products of lipid peroxidation through conjugation to glutathione (Shao et al., 2006). 
Although these enzymes work together to protect the cell, cell death can result if ROS 
production exceeds the defense capacity. In this experiment, the activity of SOD, 
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CAT, GPx and GST decreased in the TBI group. Treatment with pHL and Leo 
increased the activity of all the above enzymes. The increase in SOD, CAT and GPx 
was significant in TBI/pHL, but only the increase in SOD was significant in TBI/Leo. 
These results suggest that pHL and Leo might decrease the excessive formation of 
ROS, and enhance antioxidant ability against the progression of secondary brain 
injury induced by TBI. One possible antioxidant mechanism by which pHL or Leo 
could protect the cortex against oxidative stress following TBI might be the inhibition 
of intracellular Ca2+ which is involved in initiating the generation of different ROS 
following TBI. This may in turn attenuate pathophysiological events, including 
decreased SOD, CAT and GPx activities. 
 
It has been shown that early or late apoptotic processes are induced by oxidative stress 
(Zhao et al., 2005) and these events lead to delayed neuronal death after TBI 
(Raghupathi et al., 2000). Apoptosis can be initiated when the intrinsic or extrinsic 
pathways are activated and these result in a cascade of events downstream, which 
include the release of various apoptotic mediators from the mitochondria and 
activation of caspases (Ola et al., 2011). The Bcl-2 family of proteins includes both 
anti- and pro-apoptotic proteins which regulate apoptosis and a slight change in the 
dynamic balance of these proteins may result either in inhibition or promotion of cell 
death (Cory and Adams, 2002; Ola et al., 2011). Bax is a pro-apoptotic protein which 
is widely distributed in all cell types and is essential for apoptosis (Cory and Adams, 
2002). Bcl-xL is an anti-apoptotic protein which is required for the survival of 
neuronal cells (Motoyama et al., 1995). In the present study, we evaluated the effect 
of pHL and Leo on the expression levels of Bax and Bcl-xL in the hippocampus, using 
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western blot analysis. We found that the protein expression of Bax and Bcl-xL 
increased and decreased respectively after TBI. This trend is in accord with the level 
of Bax and Bcl-xL mRNAs in a LFP model of TBI (Strauss et al., 2004). However, 
treatment with either pHL or Leo increased the expression of Bcl-xL while it 
decreased the expression of Bax. Besides alterations in regional expression of cell 
death and cell survival genes, activation of caspase-3 (Yakovlev et al., 1997) and 
cleavage of PARP (LaPlaca et al., 1999) can also lead to apoptotic cell death 
following TBI. Caspase-3 activity increased following lateral FPI (Yakovlev et al., 
1997) and has been shown to cleave PARP in apoptotic-specific processes (Nicholson 
et al., 1995). Significant PARP proteolysis observed one week following lateral FPI 
(LaPlaca et al., 1999) most probably indicates caspase-3 activity and may contribute 
to incomplete DNA repair (Lindahl et al., 1995). Our results demonstrate decreased 
procaspase-3 and increased cleaved PARP expression after TBI which were similar to 
the study by (Hutchison et al., 2001). Both pHL and Leo treatment helped to reverse 
the effect after TBI, and this suggests that they were able to prevent caspase-3 
dependent apoptotic cell death and promote DNA repair under our experimental 
conditions. Therefore, we think that the protective effect of pHL or Leo may at least 
be partly attributed to reductions in apoptotic activity in the brain tissue after TBI.  
 
Previously, we mentioned that oxidative stress contributes to progressive 
neuropathology in TBI. Oxidative stress results from an imbalance of oxidising 
species and natural antioxidants in the body. Furthermore, it may be responsible for 
aging, cell apoptosis, and severe diseases such as cancer, Parkinson’s disease, 
Alzheimer’s disease, and even cardiovascular disorders (Giasson et al., 2002).  There 
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are epidemiological evidences correlating higher intake of components or foods with 
antioxidant abilities to lower incidence of various human morbidities or mortalities 
(Devasagayam et al., 2004). It is also clear that most dietary antioxidants have low or 
minimal toxicity, and intakes can be increased without adverse effects. Different food 
and compounds have different antioxidant abilities and one of the ways to measure is 
by performing the DPPH free radical test.  
 
In our study, the antiradical activity of pHL and Leo were measured using DPPH 
assay. The reduction capability of DPPH is determined by the decrease in its 
absorbance at 517 nm. This is based on the principle that the amount of purple DPPH 
radical chromogens decrease stoichiometrically according to the amount of exposure 
to proton radical scavengers in the extracts, while they are reduced to their yellow 
non-radical form. Figure 3-11 shows the graphs of percentage reduction of DPPH• 
radical against various concentrations of the extract for different compounds. The 
antiradical properties of the tested compounds were evaluated as EC50 DPPH. The 
EC50 is an international quantitative standard used to gauge the effectiveness of a 
drug. Specific to the study, it is the concentration of extract which reduces the free 
radical DPPH• by 50%. The lower the EC50 value, the greater the antioxidant ability 
of the sample, as a lesser amount is needed to achieve the same effect. 
 
Both pHL and Leo obtained a lower ability of reducing free radicals in relation to the 
positive control (Vitamin C). However, pHL demonstrated better DPPH radical-
scavenging activity than Leo. pHL has EC50 approximately 35-fold higher than that of 
VC while Leo can only reduce DPPH• radical by 20% at the end of the experiment. 
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We are unable to determine the EC50 of Leo in this study. The first reason might be 
Leo is less soluble in water compared to pHL and this may affect the completion of 
reaction. The second reason might be a substantially higher amount of extract or a 
long period of time is needed to achieve the same in vitro antioxidant activity as VC. 
Based on the results, we think it is impractical to obtain and use such a large amount 
of pure Leo extract for treatment. Furthermore, it may not be clinically important for 
conditions which require fast-acting drugs. 
 
From the EC50 readings, pHL showed a stronger antioxidant activity compared to Leo. 
It was also proven in our animal studies that pHL has better antioxidant and anti-
apoptotic effects than Leo, as it shows a higher percentage increase/decrease of the 
treatment outcome. The difference in activities of SOD, CAT and GPx was significant 
between both treatments. In addition, there is significant difference in expression of 
PARP, Bcl-xL and caspase-3 between both treatments. 
 
Earlier in the introduction, we mentioned that the extract of pHL consists of Leo, 
Stachydrine, Quercetin, Apigenin and Kaempferol. Among these compounds, 
Quercetin (flavonol), Apigenin (flavone) and Kaempferol (flavonol) belong to the 
group flavonoids. There are studies which show their antioxidant and anti-
inflammation properties and this may contribute to neuroprotective effects.  
 
Quercetin decreased oxidative stress and inhibit neutrophil infiltration in rats 
subjected to FPI (Schultke et al., 2005). It could also be a potent nutrient that can 
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access the brain and protect it from disorders associated with oxidative stress 
(Ishisaka et al., 2011). The administration of Kaempferol reduced striatal lesions and 
oxidative stress to protect against 3-nitropropionic acid-induced neurodegeneration in 
rats (Lagoa et al., 2009). Apigenin showed anti-neuroinflammatory effect in a murine 
microglia cell line by inhibiting the expression of iNOS responsible for the production 
of NO; this study was extended in a MCAO model and showed reduction in neuronal 
cell death through inhibition of microglia cell activation (Ha et al., 2008). 
Furthermore, Apigenin alleviates kainic acid-induced excitotoxicity by quenching 
ROS as well as inhibiting glutathione (GSH) depletion in hippocampal neurons (Han 
et al., 2012). The findings in these studies could imply that the higher antioxidant 
activity of pHL is related to the effect of flavonoids in scavenging radicals and 
preventing cell death. 
 
Leo has been observed to have better effects than pHL in stroke even when the dosage 
used for treatment was much lower than that for pHL (Loh et al., 2010). Although Leo 
is found to have stronger therapeutic effects than pHL in MCAO (Loh et al., 2010), 
and it targeted similar pathways in both models, it may not be the most ideal treatment 
for TBI.  
 
We probably need a higher dose of Leo to see its therapeutic potential for TBI. It 
might also be that the synergistic effects conferred by the mixture in pHL is stronger 





As we know, TBI involves complex pathophysiological processes which are not fully 
understood. Therefore, it may be possible that the synergistic effect of components in 





























5.1    Conclusion 
The overall pathophysiology of TBI consists of at least two classes of injury. The 
primary injury results from the initial mechanical event itself. This is followed by the 
secondary injury, which involves a cascade of biochemical changes that contributes to 
delayed tissue damage and cell death (Leker and Shohami, 2002). The cascade of 
events include processes such as excitotoxicity, free radical generation, inflammation 
and apoptosis. Therefore, we have chosen to focus on oxidative stress and apoptosis 
intervention approaches for TBI therapy in this study. Previous studies focusing on 
the antioxidant properties of TCMs have shown neuroprotective effects by scavenging 
free radicals and preventing oxidative damage of cells. These encouraging results 
prompt us to further our studies with pHL and Leo, which have been demonstrated to 
have cardioprotective effect in myocardial infarction-induced rats through its 
antioxidant effects. 
 
We have chosen the FPI model to induce brain trauma in rats for this research. Our 
left FPI model has consistently reproduced 3.7atm pressure pulse which produced 
severe tissue damage in the  ipsilateral cerebral cortex and hippocampus. Throughout 
our studies, we showed that oxidative stress is associated with TBI as the rats 
suffering from TBI had reduction of SOD, CAT, GPx and GST activities. This is 
accompanied with the increased level of apoptosis as shown by TUNEL staining. 
From western blot analysis, the expressions of Bax and cleaved PARP increased 
while the expressions of BclXL and procaspase-3 decreased. Both results indicate that 




We have achieved the first objective in this thesis, which is to verify the possible 
therapeutic potential of pHL on TBI-induced rats. We believe that the therapeutic 
effect of pHL acts through antioxidant mechanisms by improving endogenous 
antioxidant concentrations and reducing apoptosis in the brain tissue after TBI. From 
the first part of the study, we conclude that pHL confers neuroprotective effects on 
TBI by reducing oxidative stress and interfering with the apoptotic cascade. 
 
Next, we evaluated the possible role of Leo to identify if it is one of the active 
ingredients of pHL for neuroprotection. The second objective in this project was 
achieved in this experiment. Similar to pHL treatment, Leo  treatment has antioxidant 
effect by improving endogenous antioxidant concentrations in the brain tissue. It also 
interfered with apoptosis signalling. 
 
The third objective in this project was achieved in experiment III. The results obtained 
from experiment III showed that the antioxidant capacity of pHL was higher, and the 
protective effects were better compared to Leo after TBI. .  
 
In summary, our data show that both pHL and Leo confer protection to brain tissue 
following TBI. This protection may be mediated through antioxidative and 
antiapoptotic mechanisms.However, pHL has a higher antioxidant capacity, therefore 
it is able to reduce oxidative stress and apoptosis more effectively than Leo. Further 





5.2    Limitations of study 
The difficulty encountered when studying TBI is due to the limitation of collecting 
post-mortem tissue, at the time points after onset of TBI while brain damage occurs. 
Therefore, the majority of TBI studies and development of its therapy have relied on 
animal models. In addition to animal models, attempts have been made to develop in 
vitro models of TBI which recapitulate distinct components of the mechanical 
stimulus. The addition of chemicals can also be used to induce major cellular injury 
pathways. Nonetheless, none of these models completely represents the phenomenon 
in human TBI. As a result, there are numerous failed clinical trials with agents which 
have shown potential therapeutic effect under experimental conditions. Some reasons 
include lack of efficacy, inadequate dosing in humans or serious side-effects, 
indicating that a much more complicated secondary injury cascade happens in human 
TBI. Therefore, more detailed information on TBI pathophysiology is urgently needed.  
 
However, this does not undermine the importance and value of the current research, 
as every single research provides valuable information on specific mechanisms for the 
understanding of TBI and possible design for TBI therapies. Similarly, many 
synthetic antioxidants showing promising therapeutic potential in animal models of 
TBI have failed to develop into drugs for humans. Chemical opening due to osmotic 
differential pressure at BBB tight junction or pathological openings due to trauma or 
pathogenic causes can transfer molecules across the BBB (Uttara et al., 2009). A 
major concern of administering synthetic antioxidant is their ability to cross the BBB. 
The ability to passively cross the BBB depends on the molecular size of the molecule 
(less than 500D),. charge (low hydrogen bonding capabilities) and lipophilicity (the 
more lipophilic, the better the transport) (Lipinski et al., 2001)  
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In order for a molecule that is known to be active against a CNS target to penetrate 
the BBB, it can be modified to reduce the number of polar groups or lipid carriers can 
be used for its transport (Gabathuler, 2010). Inability of antioxidants to cross the BBB 
result in their inefficacy for TBI therapy. 
 
Although many TCM have shown therapeutic effects in various diseases and 
contribute substantially to human health, pitfalls and shortcomings in herbal 
production do exist. Standardization, effective manufacturing quality control and 
supervision are still inadequate. Clinical trials are needed to completely evaluate the 
effectiveness and efficacy of TCM. Modern science and technology should be applied 
in the development, while complete quality control system should be employed in the 
manufacturing of TCM. 
 
5.3    Future studies 
 
5.3.1    Varying treatment strategies 
5.3.1.1    Isolating other active ingredients in pHL for study in TBI 
Besides Leo, other chemicals present in the extract consist of Quercetin, Kaempferol, 
Apigenin and Stachydrine. Among these, Quercetin, Kaempferol and Apigenin are 
flavanoids. They are known to have relatively high antioxidant activities, therefore 




5.3.1.2    Combination of pHL or Leo with other secondary injury therapies or 
western drugs 
The multiple pathways involved in the secondary injury cascade of TBI which lead to 
cell injury suggest that there is considerable potential for additive or synergistic 
benefit from combined therapies. Different therapeutic targets make the treatment 
complete and improve the outcome. Currently,western drugs are mainly used for the 
management of primary injury in TBI. We hope that with the therapeutic information 
obtained from Chinese herbs, such as pHL and Leo, we could combine them with 
western drugs to potentiate the therapeutic outcome and possibly minimize the size 
effects.  
 
5.3.2    Investigating the pathways involved in TBI 
5.3.2.1    pHL or Leo on the expression of apoptotic pathway proteins at earlier 
time points of TBI 
pHL and Leo are shown to reduce BAX and PARP protein expression while 
increasing Bcl-XL and caspase-3 protein expression on day 7 after TBI in the present 
study. The demonstration of protein expression at selected earlier time points after 
TBI treatment will provide more information, to help us better understand the 
mechanism(s) involved in TBI-induced brain damage. 
 
5.3.2.2   The role of iInflammation in TBI 
As mentioned in the introduction, inflammation is one of the events involved in the 
secondary injury cascade. Leo has also exerted beneficial effects in inflammatory 
conditions in human endothelial cells (Liu et al., 2012a; Liu et al., 2012b). We can 
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study proteins which are activated during an inflammatory response. Examples of 
these proteins are TNFα, IL-6, ICAM-1, VCAM-1, and COX-2. 
 
5.4    Future perspectives 
The acute treatment of TBI to prevent neuronal injury and to improve neurological 
outcome remains a challenging task. Many experimental models show a series of 
complex signalling cascades happening after TBI which leads to cell death. These 
experiments continually suggest a variety of methods for inhibiting the progress of 
secondary injury. In the long run, we would still be required to understand the 
multifaceted molecular processes that determine the final cell fate, in order to identify 
and develop novel therapies. 
 
In recent years, a tremendous effort has been made to elucidate and further understand 
oxidative stress and apoptosis in TBI. Oxidative stress and apoptosis do not happen in 
isolation, but interplay among other signalling pathways. Although results from 
clinical trials were not promising, investigations in this field have constantly inspired 
an increased interest among researchers for the development of antioxidant TBI 
therapies. However, this idea is still under development and needs time before it can 
be put to use. The reasons are the lack of knowledge in potential toxic effect of long 
term drug usage in animals, and lack of efficient methods to regulate drug delivery to 
the tissue of interest. Future development of drugs which are able to cross the BBB 




In future, we expect to see the identification of several other therapeutic targets and 
continued refinement of existing therapeutic agents for TBI. Therapeutic benefits of 
TCM have been recognized for centuries. Studies focusing on antioxidant properties 
of Chinese herbs have also shown promising therapeutic effects against oxidative 
stress in TBI, resulting in lesser cellular damage and cell death. Although there is lack 
of evidence and clarification in the mechanisms of TCM, they are still widely 
acceptable in Asia and beginning to be accepted by other parts of the world. 
Nevertheless, modification and reconstitution of TCM remain to be a challenge to 
chemists, researchers and the pharmaceutical industry.  
 
Despite all the setbacks, pharmacological modification of oxidative damage is still 
believed to be one of the most promising avenue in TBI therapy development. Since 
pHL and Leo restore the endogenous antioxidant level, inhibit apoptosis and limit the 
injury from trauma, they can be further evaluated for development into 
pharmaceuticals, or possibly combined with commercial drugs to achieve better 
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